What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2021-11-24 compared with 2020-12-28 · 1223 added, 1082 removed, 65 unchanged (97% of the section changed)

Life Sciences Corp.

is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by

applying precision medicine to central nervous system (“CNS”) diseases with high unmet need.

We analyze genomic data

from clinical studies to identify biomarkers, which we use to select patients that will receive the therapeutic benefit for the

treatment of neurodegenerative and neurodevelopmental diseases.

lead compound, ANAVEX ® 2-73, is being developed to treat Alzheimer’s disease, Parkinson’s disease and

potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological

monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (“MECP2”).

Overview and Strategy

Anavex Life Sciences Corp.

is a clinical stage

biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous

system (“CNS”) diseases with high unmet need.

We analyze genomic data from clinical studies to identify biomarkers,

which we use to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental

Our lead compound, ANAVEX ® 2-73,

is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases,

including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked

gene, methyl-CpG-binding protein 2 (“MECP2”).

We currently have two core programs and two

1 unchanged sentence

Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental

following table summarizes key information about our programs:

has a portfolio of compounds varying in sigma-1 receptor (S1R) binding activities.

The SIGMAR1 gene encodes the S1R protein, which

is an intracellular chaperone protein with important roles in cellular communication.

S1R is also involved in transcriptional

regulation at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated.

to validate the ability of our compounds to activate quantitatively the S1R, we performed, in collaboration with Stanford University,

a quantitative Positron Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX ® 2-73

target engagement or receptor occupancy (RO) with S1R in the brain.

diseases are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells.

In pediatric diseases

like Rett syndrome or infantile spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation.

In neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases, chronic cellular stress is possibly caused

by age-correlated buildup of cellular insult and hence chronic cellular stress.

Specifically, defects in homeostasis of protein

or ribonucleic acid (“RNA”) lead to the death of neurons and dysfunction of the nervous system.

The spreading of protein

aggregates resulting in a proteinopathy, a characteristic finding in Alzheimer’s and Parkinson’s diseases that results

from disorders of protein synthesis, trafficking, folding, processing or degradation in cells.

The clearance of macromolecules

in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in nerve cells.

Alzheimer’s disease pathology is characterized by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates

of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation of microglia.

With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX ® 2-73, our approach is to restore cellular balance,

Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental

and neurodegenerative disease progression.

ANAVEX ® 2-73-specific

full genomic analysis of Alzheimer’s disease (AD) patients treated with ANAVEX ® 2-73 resulted in the identification

of actionable genetic variants.

A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX ® 2-73

and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX ® 2-73-specific

biomarker hypothesis.

It is expected that excluding patients with these two identified biomarker variants (approximately

10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically

significant improved functional and cognitive scores.

The following table summarizes key information about our programs:

* = Orphan Drug Designation by the FDA;

Dashed lines indicate planned clinical studies

Anavex has a portfolio of compounds varying

in sigma-1 receptor (S1R) binding activities.

The SIGMAR1 gene encodes the S1R protein, which is an intracellular chaperone protein

with important roles in cellular communication.

S1R is also involved in transcriptional regulation at the nuclear envelope and

restores homeostasis and stimulates recovery of cell function when activated.

In order to validate the ability of our compounds

to activate quantitatively the S1R, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography

(PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX ® 2-73 target engagement or receptor occupancy

(RO) with S1R in the brain.

Reyes S et al., Sci Rep.

2021 Aug 25;11(1):17150

Cellular Homeostasis

Many diseases are possibly directly caused

by chronic homeostatic imbalances or cellular stress of brain cells.

In pediatric diseases like Rett syndrome or infantile spasms,

the chronic cellular stress is possibly caused by the presence of a constant genetic mutation.

In neurodegenerative diseases, such

as Alzheimer’s and Parkinson’s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular

insult and hence chronic cellular stress.

Specifically, defects in homeostasis of protein or ribonucleic acid (“RNA”)

lead to the death of neurons and dysfunction of the nervous system.

The spreading of protein aggregates resulting in a proteinopathy,

a characteristic finding in Alzheimer’s and Parkinson’s diseases that results from disorders of protein synthesis,

trafficking, folding, processing or degradation in cells.

The clearance of macromolecules in the brain is particularly susceptible

to imbalances that result in aggregation and degeneration in nerve cells.

For example, Alzheimer’s disease pathology is characterized

by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are a

marker of other diseases known as tauopathies as well as inflammation of microglia.

With the SIGMAR1 activation through SIGMAR1

agonists like ANAVEX ® 2-73, our approach is to restore cellular balance, i.e.

Therapies that correct

defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative disease progression.

ANAVEX ® 2-73-specific Biomarkers

A full genomic analysis of Alzheimer’s

disease (AD) patients treated with ANAVEX ® 2-73 resulted in the identification of actionable genetic variants.

significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX ® 2-73 and COMT, a gene involved

in memory function, on the drug response level was identified, leading to an early ANAVEX ® 2-73-specific biomarker

It is expected that excluding patients with SIGMAR1 identified biomarker variant (approximately 10%-20% of

the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant

improved functional and cognitive scores.

The consistency between the identified DNA and RNA data related to ANAVEX ® 2-73,

3 unchanged sentences

like Parkinson’s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX ® 2-73 is currently studied.

Studies Overview

November 2016, we completed a Phase 2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for

ANAVEX ® 2-73 in mild-to-moderate Alzheimer’s patients.

This open-label randomized trial met both primary and

secondary endpoints and was designed to assess the safety and exploratory efficacy of ANAVEX ® 2-73 in 32 patients.

ANAVEX ® 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress

levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer’s

The Phase 2a trial demonstrated positive pharmacokinetic (PK) and pharmacodynamic (PD) data, which established a concentration-effect

relationship between ANAVEX ® 2-73 and study measurements.

These measures obtained from all patients who participated

in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity.

Additionally,

the study appears to show that ANAVEX ® 2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which

also targets the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.

consecutive trial extensions for the Phase 2a trial have allowed participants who completed the 52-week PART B of the study to

continue taking ANAVEX ® 2-73, providing an opportunity to gather extended safety data for a cumulative time period

of five years.

In August 2020, patients completing these Phase 2a trial extensions were granted continued access to treatment

with ANAVEX ® 2-73 through the Australian Government Department of Health – Therapeutic Goods Administration

(TGA) compassionate use Special Access Scheme.

larger Phase 2b/3 double-blind, placebo-controlled study of ANAVEX ® 2-73 in Alzheimer’s disease

commenced in August 2018.

The Phase 2b/3 study will enroll approximately 450 patients for 48 weeks, randomized 1:1:1 to two

different ANAVEX ® 2-73 doses or placebo.

Clinical Studies Overview

Alzheimer’s Disease

In November 2016, we completed a Phase 2a clinical

trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for ANAVEX ® 2-73 in mild-to-moderate Alzheimer’s

This open-label randomized trial met both primary and secondary endpoints and was designed to assess the safety and exploratory

efficacy of ANAVEX ® 2-73 in 32 patients.

ANAVEX ® 2-73 targets sigma-1 and muscarinic receptors, which

have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse

the pathological hallmarks observed in Alzheimer’s disease.

The Phase 2a trial demonstrated positive pharmacokinetic (PK)

and pharmacodynamic (PD) data, which established a concentration-effect relationship between ANAVEX ® 2-73 and study

measurements.

These measures obtained from all patients who participated in the entire 57 weeks include exploratory cognitive and

functional scores as well as biomarker signals of brain activity.

Additionally, the study appears to show that ANAVEX ® 2-73

activity is enhanced by its active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately

twice as long as the parent molecule.

Two consecutive trial extensions for the Phase

2a trial have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX ® 2-73,

providing an opportunity to gather extended safety data for a cumulative time period of five years.

In August 2020, patients completing

these Phase 2a trial extensions were granted continued access to treatment with ANAVEX ® 2-73 through the Australian

Government Department of Health – Therapeutic Goods Administration (TGA) compassionate use Special Access Scheme.

A larger Phase 2b/3 double-blind, placebo-controlled

study of ANAVEX ® 2-73 in Alzheimer’s disease commenced in August 2018.

The Phase 2b/3 study enrolled 509 patients

for 48 weeks, randomized 1:1:1 to two different ANAVEX ® 2-73 doses or placebo.

The trial commenced in Australia;

and during fiscal 2020 additional

regions were added in the United Kingdom, The Netherlands, Germany and Canada.

The ANAVEX ® 2-73 Phase 2b/3

study design incorporates genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a study.

Primary and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through

Alzheimer’s Disease Assessment Scale – Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating – Sum of

Boxes for cognition and function (CDR-SB).

October 2019, we initiated a long-term open label extension study of ANAVEX ® 2-73, entitled the ATTENTION-AD study,

for patients who have completed the 48-week Phase 2b/3 placebo-controlled trial referenced above.

This study is expected to last

two years and will give patients the opportunity to continue their treatment.

February 2016, we presented positive preclinical data for ANAVEX ® 2-73 in Rett syndrome, a rare neurodevelopmental

The study was funded by the International Rett Syndrome Foundation (“Rettsyndrome.org”).

In January 2017,

we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter

Phase 2 clinical trial of ANAVEX ® 2-73 for the treatment of Rett syndrome.

This award was received in quarterly

instalments which commenced during fiscal 2018.

March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX ® 2-73 for

and during fiscal 2020 additional regions were added in the United Kingdom, The Netherlands, Germany, and Canada.

The ANAVEX ® 2-73

Phase 2b/3 study design incorporates genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a

Primary and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through Alzheimer’s

Disease Assessment Scale – Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating – Sum of Boxes for cognition

and function (CDR-SB).

The study completed enrollment in June 2021, exceeding the 450 patients enrollment target at 52 sites across

North America, Europe and Australia.

In October 2019, we initiated a long-term open

label extension study of ANAVEX ® 2-73, entitled the ATTENTION-AD study, for patients who have completed the 48-week

Phase 2b/3 placebo-controlled trial referenced above.

This study is expected to last two years and will give patients the opportunity

to continue their treatment.

Upon request by patients, caretakers and investigators, this extension study was extended by one further

Rett Syndrome

In February 2016, we presented positive preclinical

data for ANAVEX ® 2-73 in Rett syndrome, a rare neurodevelopmental disease.

The study was funded by the International

Rett Syndrome Foundation (“Rettsyndrome.org”).

In January 2017, we were awarded a financial grant from Rettsyndrome.org

of a minimum of $0.6 million to cover some of the costs of a multicenter Phase 2 clinical trial of ANAVEX ® 2-73 for

the treatment of Rett syndrome.

The studies will be conducted in a range of patient age demographics and geographic regions.

The first Phase 2 study, which took place

in the United States, was completed in December 2020.

This trial was a randomized double-blind, placebo-controlled safety, tolerability,

pharmacokinetic and efficacy study of oral liquid ANAVEX ® 2-73formulation in 25 adult female patients with Rett

syndrome over a 7-week treatment period including ANAVEX ® 2-73-specific genomic precision medicine biomarkers.

This award was received in quarterly instalments which commenced during fiscal 2018.

In March 2019, we commenced the first Phase

2 clinical trial in a planned Rett syndrome program of ANAVEX ® 2-73 for the treatment of Rett syndrome.

are being conducted in a range of patient age demographics and geographic regions, utilizing a convenient oral liquid once-daily

formulation of ANAVEX ® 2-73.

The first Phase 2 study, which took

place in the United States, was completed in December 2020.

This trial was a randomized double-blind, placebo-controlled safety,

tolerability, pharmacokinetic and efficacy study of oral liquid ANAVEX ® 2-73 formulation in 25 adult female patients

with Rett syndrome over a 7-week treatment period including ANAVEX ® 2-73-specific genomic precision medicine biomarkers.

The primary endpoint of the trial was safety.

The convenient oral liquid once-daily dosing of 5 mg ANAVEX ® 2-73

was well-tolerated and demonstrated dose-proportional PK (pharmacokinetics).

All secondary efficacy endpoints of the trial showed

statistically significant and clinically meaningful, drug exposure-dependent response in the Rett Syndrome Behaviour Questionnaire

(RSBQ) Total scores, when compared to placebo, in the ITT cohort (all participants, p = 0.048).

66.7% of ANAVEX ® 2-73

treated subjects showed a statistically significant improvement in drug exposure-dependent RSBQ response as compared to 10% of

the subjects on placebo in the ITT cohort (all participants, p = 0.011).

ANAVEX ® 2-73 treatment resulted in a sustained

improvement in Clinical Global Impression Improvement (CGI-I) scores throughout the 7-week study, when compared to placebo in

the ITT cohort (all participants, p = 0.014).

86.7% of ANAVEX ® 2-73 treated subjects showed a statistically significant

CGI-I response, defined as sustained improvement to treatment, as compared to 40% of the subjects on placebo in the ITT cohort

The dosing of 5 mg ANAVEX ® 2-73 was well-tolerated and demonstrated

dose-proportional PK (pharmacokinetics).

All secondary efficacy endpoints of the trial showed statistically significant and clinically

meaningful, drug exposure-dependent response in the Rett Syndrome Behaviour Questionnaire (RSBQ) Total scores, when compared to

placebo, in the ITT cohort (all participants, p = 0.048).

66.7% of ANAVEX ® 2-73 treated subjects showed a statistically

significant improvement in drug exposure-dependent RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort

(all participants, p = 0.011).

Consistent with previous ANAVEX ® 2-73 clinical trials, patients carrying the common

form of the SIGMAR1 gene treated with ANAVEX ® 2-73 experienced stronger improvements in the prespecified efficacy

ANAVEX ® 2-73 treatment resulted in a sustained improvement in Clinical Global Impression

Improvement (CGI-I) scores throughout the 7-week study, when compared to placebo in the ITT cohort (all participants, p = 0.014).

86.7% of ANAVEX ® 2-73 treated subjects showed a statistically significant CGI-I response, defined as sustained improvement

to treatment, as compared to 40% of the subjects on placebo in the ITT cohort (all participants, p = 0.014).

Consistent with previous

ANAVEX ® 2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX ® 2-73

experienced stronger improvements in the prespecified efficacy endpoints.

The second Phase 2 study of ANAVEX ® 2-73

1 unchanged sentence

This study is taking place in Australia and

the United Kingdom using a convenient once-daily oral liquid ANAVEX ® 2-73 formulation at a higher dose than the

the United Kingdom using a higher dose than the U.S.

based Phase 2 study for Rett syndrome.

The study will evaluate the safety and efficacy of ANAVEX ® 2-73 in approximately

33 patients over a 7-week treatment period including ANAVEX ® 2-73 specific precision medicine biomarkers.

who participate in the study will be eligible to receive ANAVEX ® 2-73 under a voluntary open label extension protocol.

July 2020, we commenced the third study of ANAVEX ® 2-73 for the treatment of Rett syndrome, called the EXCELLENCE

This Phase 2/3 study in pediatric patients with Rett syndrome is using a convenient once-daily oral liquid ANAVEX ® 2-73

The study will evaluate the safety and efficacy of ANAVEX ® 2-73 in at least 69 pediatric patients,

This randomized, placebo-controlled

study will evaluate the safety and efficacy of ANAVEX ® 2-73 in approximately 33 patients over a 7-week treatment

period including ANAVEX ® 2-73 specific precision medicine biomarkers.

All patients who participate in the study will

be eligible to receive ANAVEX ® 2-73 under a voluntary open label extension protocol.

The AVATAR study is expected

to read out topline data around year end 2021.

In July 2020, we commenced the third

study of ANAVEX ® 2-73 for the treatment of Rett syndrome, called the EXCELLENCE study.

This Phase 2/3 study in pediatric

patients with Rett syndrome will evaluate the safety and efficacy of ANAVEX ® 2-73 in approximately 84 pediatric patients,

aged 5 to 18, over a 12-week treatment period incorporating ANAVEX ® 2-73 specific precision medicine biomarkers.

All patients who participate in the study will be eligible to receive ANAVEX ® 2-73 under a voluntary open label

extension protocol.

September 2016, we presented positive preclinical data for ANAVEX ® 2-73 in Parkinson’s disease, which demonstrated

significant improvements on all measures:

behavioral, histopathological, and neuroinflammatory endpoints.

The study was funded

by the Michael J.

Fox Foundation.

Additional data was announced in October 2017 from the model for experimental parkinsonism.

The data presented indicates that ANAVEX ® 2-73 induces robust neurorestoration in experimental parkinsonism.

encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer’s

disease trial, support the notion that ANAVEX ® 2-73 is a promising clinical candidate drug for Parkinson’s

disease dementia.

October 2020, we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX ® 2-73

in Parkinson’s Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of

All patients who participate in the study will be eligible to receive ANAVEX ® 2-73 under a voluntary open label extension

Parkinson’s Disease

The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different

ANAVEX ® 2-73 doses, 30mg and 50mg, or placebo.

The ANAVEX ® 2-73 Phase 2 PDD study design incorporated

genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a study.

study found that ANAVEX ® 2-73 was safe and well tolerated in oral doses up to 50mg once daily.

The results show

clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized

assessment system analysis.

The study confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker in

response to ANAVEX ® 2-73.

August 2020, we announced a financial commitment by Shake It Up Australia Foundation for Parkinson’s Research to fund up

to 50% of the costs of an Australian clinical study to develop ANAVEX ® 2-73 for the disease modifying treatment

of Parkinson’s disease.

The financial commitment would be made through private placement purchases of our common stock at

200% of the fair market value on the purchase date and will be contingent upon the completion of certain clinical trial milestones

relating to the proposed clinical trial.

The proposed clinical trial will use a convenient, once-daily oral ANAVEX ® 2-73

formulation to confirm the previously established potential disease modifying features of ANAVEX ® 2-73 in an animal

model of Parkinson’s disease.

Safety and efficacy will be investigated in an appropriately powered placebo-controlled clinical

study of Parkinson’s disease patients over at least 48-weeks including ANAVEX ® 2-73-specific precision medicine

Frontotemporal

July 2020, we commenced the First-in-Human Phase 1 clinical trial of ANAVEX ® 3-71, which was previously granted

orphan drug designation for the treatment of Frontotemporal Dementia (FTD) by the FDA.

ANAVEX ® 3-71 is an orally

administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative

In preclinical studies, ANAVEX ® 3-71 demonstrated disease-modifying

activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits,

amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.

Phase 1 clinical trial will be a prospective double-blind, randomized, placebo-controlled study.

A total of at least 36 healthy

male and female subjects will be included.

Single escalating doses of ANAVEX ® 3-71 will be administered in order

to evaluate the safety, tolerability, and pharmacokinetics (PK) of ANAVEX ® 3-71 and the effects of food and gender

on its PK in healthy volunteers.

This study is expected to be followed by longer duration dosing including patients with FTD or

other dementia indications with unmet medical need, incorporating exploratory efficacy and disease biomarker measures .

research and development pipeline includes ANAVEX ® 2-73 currently in three different clinical study indications,

and several other compounds in different stages of clinical and pre-clinical study.

proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with unique modes of action, based on

our understanding of sigma receptors.

Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative

nature, including Alzheimer’s disease, as well as of neurodevelopmental nature, like Rett syndrome.

When bound by the appropriate

ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin

or development) of disease.

Multiple viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial

apoptosis and other related cellular processes, in order to ensure survival and replication.

Hence, it is possible that S1R could

play a role in modulating the cellular response to viral infection and ameliorate pathogenesis.

that have been subjects of our research include the following:

ANAVEX ® 2-73

(blarcamesine)

ANAVEX ® 2-73

may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.

Rett syndrome, administration of ANAVEX ® 2-73 resulted in both significant and dose related improvements in an array

of behavioral paradigms in the MECP2 HET Rett syndrome disease model.

In addition, in a further experiment sponsored by Rettsyndrome.org,

ANAVEX ® 2-73 was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which

advanced pathology is evident.

Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice.

with ANAVEX ® 2-73 for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome

disease mouse.

Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX ® 2-73 starting at ~5.5 weeks of age

was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular coordination, balance,

motor learning and muscular strengths, some of the core deficits observed in Rett syndrome.

Administration of ANAVEX ® 2-73

resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome

disease model.

March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX ® 2-73 for

the treatment of Rett syndrome.

This study, which took place in the United States, was completed in December 2020, however two

other clinical trials in Rett syndrome, the AVATAR study and the EXCELLENCE study, are still underway.

The studies are being conducted

in a range of patient age demographics and geographic regions, as more fully described above under Clinical Studies Overview

In September 2016, we presented positive

preclinical data for ANAVEX ® 2-73 in an animal model of Parkinson’s disease, which demonstrated significant

improvements on behavioral, histopathological, and neuroinflammatory endpoints.

The study was funded by the Michael J.

Fox Foundation.

Additional data announced in October 2017 indicates that ANAVEX ® 2-73 induces robust neurorestoration in experimental

Parkinsonism.

The encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the

Alzheimer’s disease trial, support the notion that ANAVEX ® 2-73 is a promising clinical candidate drug for

Parkinson’s disease dementia.

In October 2020, we completed a double-blind,

randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX ® 2-73 in Parkinson’s Disease Dementia

(PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease.

study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX ® 2-73 doses, 30mg

and 50mg, or placebo.

The ANAVEX ® 2-73 Phase 2 PDD study design incorporated genomic precision medicine biomarkers

identified in the ANAVEX ® 2-73 Phase 2a Alzheimer’s disease study.

Within this study ANAVEX ® 2-73

was safe and well tolerated in oral doses up to 50mg once daily.

The results show clinically meaningful, dose-dependent, and statistically

significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis.

Treatment with ANAVEX ® 2-73

also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson’s disease symptom

severity, MDS-UPDRS Total score on top of standard of care including dopaminergic therapy, levodopa and other anti-PD medications

after 14 weeks of treatment, suggesting ANAVEX ® 2-73’s potential global capability of slowing and reversing

symptoms that progress in Parkinson’s disease.

The study confirmed the precision medicine approach of targeting SIGMAR1 as

a genetic biomarker in response to ANAVEX ® 2-73.

In January 2021, we announced we were

awarded a research grant of $1.0 million from The Michael J.

Foundation for Parkinson’s Research (MJFF) to develop ANAVEX ® 2-73 for the treatment of Parkinson’s

The award will explore utilization of PET imaging biomarkers to enable measurement of target engagement and pathway activation

of the sigma-1 receptor (SIGMAR1) with clinically relevant doses in people with Parkinson’s disease.

Frontotemporal Dementia

In July 2020, we commenced the First-in-Human

Phase 1 clinical trial of ANAVEX ® 3-71, which was previously granted orphan drug designation for the treatment of

Frontotemporal Dementia (FTD) by the FDA.

ANAVEX ® 3-71 is an orally administered small molecule targeting sigma-1

and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.

In preclinical studies, ANAVEX ® 3-71

demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice,

including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.

1 clinical trial will be a prospective double-blind, randomized, placebo-controlled study.

A total of at least 36 healthy male

and female subjects will be included.

Single escalating doses of ANAVEX ® 3-71 will be administered in order to evaluate

the safety, tolerability, and pharmacokinetics (PK) of ANAVEX ® 3-71 and the effects of food and gender on its PK

in healthy volunteers.

This study is expected to be followed by longer duration dosing including patients with FTD or other dementia

indications with unmet medical need, incorporating exploratory efficacy and disease biomarker measures .

Our research and development pipeline includes

ANAVEX ® 2-73 currently in three different clinical study indications, and several other compounds in different stages

of clinical and pre-clinical study.

Our proprietary SIGMACEPTOR™ Discovery

Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors.

receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer’s

disease, as well as of neurodevelopmental nature, like Rett syndrome.

When bound by the appropriate ligands, sigma receptors influence

the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular

processes, in order to ensure survival and replication.

Hence, it is possible that S1R could play a role in modulating the cellular

response to viral infection and ameliorate pathogenesis.

Compounds that have been subjects of our research

include the following:

ANAVEX ® 2-73 (blarcamesine)

ANAVEX ® 2-73 may offer a disease-modifying

approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.

In Rett syndrome, administration of ANAVEX ® 2-73

resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease

In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX ® 2-73 was evaluated in automatic

visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident.

Vehicle-treated MECP2

mice demonstrated fewer automatic visual responses than wild-type mice.

Treatment with ANAVEX ® 2-73 for four weeks

significantly increased the automatic visual response in the MECP2 Rett syndrome disease mouse.

Additionally, chronic oral dosing

daily for 6.5 weeks of ANAVEX ® 2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease

mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths, some of the

core deficits observed in Rett syndrome.

Administration of ANAVEX ® 2-73 resulted in both significant and dose related

improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.

In March 2019, we commenced the first Phase

2 clinical trial in a planned Rett syndrome program of ANAVEX ® 2-73 for the treatment of Rett syndrome.

which took place in the United States, was completed in December 2020, however two other clinical trials in Rett syndrome, the

AVATAR study and the EXCELLENCE study, are still underway.

The studies are being conducted in a range of patient age demographics

and geographic regions, as more fully described above under Clinical Studies Overview – Rett Syndrome .

In May 2016 and June 2016, the FDA granted

Orphan Drug Designation to ANAVEX ® 2-73 for the treatment of Rett syndrome and infantile spasms, respectively.

November 2019, the FDA granted to ANAVEX ® 2-73 the Rare Pediatric Disease (RPD) designation for the treatment of

Rett syndrome.

May 2016 and June 2016, the FDA granted Orphan Drug Designation to ANAVEX ® 2-73 for the treatment of Rett syndrome

and infantile spasms, respectively.

In November 2019, the FDA granted to ANAVEX ® 2-73 the Rare Pediatric Disease

(RPD) designation for the treatment of Rett syndrome.

The RPD designation provides priority review by the FDA to encourage the

development of treatments for rare pediatric diseases.

in February 2020, the FDA granted Fast Track designation for the ANAVEX ® 2-73 clinical development program for the

treatment of Rett syndrome.

The FDA Fast Track program is designed to facilitate and expedite the development and review of new

drugs to address unmet medical needs in the treatment of serious and life-threatening conditions.

Parkinson’s disease, data demonstrates significant improvements and restoration of function in a disease modifying animal

model of Parkinson’s disease.

Significant improvements were seen on all measures tested:

behavioral, histopathological,

and neuroinflammatory endpoints.

In October 2020, we completed a double-blind, randomized, placebo-controlled proof-of-concept

Phase 2 trial with ANAVEX ® 2-73 in Parkinson’s Disease Dementia (PDD), to study the effect of the compound

on both the cognitive and motor impairment of Parkinson’s disease.

The Phase 2 study enrolled approximately 132 patients

for 14 weeks, randomized 1:1:1 to two different ANAVEX ® 2-73 doses, 30mg and 50mg, or placebo.

The ANAVEX ® 2-73

Phase 2 PDD study design incorporated genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase

study found that ANAVEX ® 2-73 was safe and well tolerated in oral doses up to 50mg once daily.

The results show

clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized

assessment system analysis.

We anticipate conducting further clinical trials of ANAVEX ® 2-73 in Parkinson’s

disease dementia after submitting the results of the study to the FDA to obtain regulatory guidance.

Alzheimer’s disease (AD) animal models, ANAVEX ® 2-73 has shown pharmacological, histological and behavioral

evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent

affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors.

In addition, ANAVEX ® 2-73

has shown a potential dual mechanism which may impact both amyloid and tau pathology.

In a transgenic AD animal model Tg2576,

ANAVEX ® 2-73 induced a statistically significant neuroprotective effect against the development of oxidative stress

in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that is apparently

amyloid-beta independent.

It also statistically alleviated the learning and memory deficits developed over time in the animals,

regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.

on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX ® 2-73.

In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg.

This dose is above the equivalent

dose shown to have positive effects in mouse models of AD.

There were no significant changes in laboratory or electrocardiogram

(ECG) parameters.

ANAVEX ® 2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some

Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were

moderate in severity and reversible.

The RPD designation provides priority review by the FDA to encourage the development of treatments for rare pediatric

Further, in February 2020, the FDA granted

Fast Track designation for the ANAVEX ® 2-73 clinical development program for the treatment of Rett syndrome.

FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical

needs in the treatment of serious and life-threatening conditions.

For Parkinson’s disease, data demonstrates

significant improvements and restoration of function in a disease modifying animal model of Parkinson’s disease.

improvements were seen on all measures tested:

behavioral, histopathological, and neuroinflammatory endpoints.

In October 2020,

we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX ® 2-73 in Parkinson’s

Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease.

The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX ® 2-73

doses, 30mg and 50mg, or placebo.

The ANAVEX ® 2-73 Phase 2 PDD study design incorporated genomic precision medicine

biomarkers identified in the ANAVEX ® 2-73 Phase 2a Alzheimer’s disease study.

The study found that ANAVEX ® 2-73

was safe and well tolerated in oral doses up to 50mg once daily.

The results show clinically meaningful, dose-dependent, and statistically

significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis.

We anticipate conducting

further clinical trials of ANAVEX ® 2-73 in Parkinson’s disease dementia after submitting the results of the

study to the FDA to obtain regulatory guidance.

In Alzheimer’s disease (AD) animal models,

ANAVEX ® 2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic,

anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities

to M1-4 type muscarinic receptors.

In addition, ANAVEX ® 2-73 has shown a potential dual mechanism which may impact

amyloid, tau pathology and inflammation.

In a transgenic AD animal model Tg2576, ANAVEX ® 2-73 induced a statistically

significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased

the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent.

It also statistically

alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working

memory and long-term spatial reference memory.

Based on the results of pre-clinical testing,

we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX ® 2-73.

In this Phase 1

SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg.

This dose is above the equivalent dose shown

to have positive effects in mouse models of AD.

There were no significant changes in laboratory or electrocardiogram (ECG) parameters.

ANAVEX ® 2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects.

adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity

and reversible.

These side effects are often seen with drugs that target CNS conditions, including AD.

December 2014, a Phase 2a clinical trial was initiated for ANAVEX ® 2-73, for the treatment of Alzheimer’s

The open-label randomized trial was designed to assess the safety and exploratory efficacy of ANAVEX ® 2-73

in 32 patients with mild-to-moderate Alzheimer’s disease.

ANAVEX ® 2-73 targets sigma-1 and muscarinic receptors,

which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and

to reverse the pathological hallmarks observed in Alzheimer’s disease.

The Phase 2a study met both primary and secondary

objectives of the study.

July 2018, we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study.

More than 33,000

genes were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &

RNA data in patients exposed to ANAVEX ® 2-73.

The analysis identified genetic variants that impacted response to

ANAVEX ® 2-73, among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX ® 2-73.

Results showed that study participants with the common SIGMAR1 wild type gene variant, which is about 80 percent of the population

worldwide, demonstrated improved cognitive (MMSE) and the functional (ADCS-ADL) scores.

The results from this evaluation have

been used to establish a precision medicine approach in subsequent clinical trials, since these signatures can now be applied

to neurological indications tested in clinical studies with ANAVEX ® 2-73 including Alzheimer’s disease, Parkinson’s

disease dementia and Rett syndrome.

In December 2014, a Phase 2a clinical trial

was initiated for ANAVEX ® 2-73, for the treatment of Alzheimer’s disease.

The open-label randomized trial was

designed to assess the safety and exploratory efficacy of ANAVEX ® 2-73 in 32 patients with mild-to-moderate Alzheimer’s

ANAVEX ® 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1

and muscarinic receptors.

Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s.

The Phase 2a study met both primary and secondary objectives of the study.

In July 2018, we presented

the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study.

More than 33,000 genes were analyzed

using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA & RNA data in patients

exposed to ANAVEX ® 2-73.

The analysis identified genetic variants that impacted response to ANAVEX ® 2-73,

among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX ® 2-73.

Results showed that study

participants with the common SIGMAR1 wild type gene variant, which is about 80 percent of the population worldwide, demonstrated

improved cognitive (MMSE) and the functional (ADCS-ADL) scores.

The results from this evaluation have been used to establish a

precision medicine approach in subsequent clinical trials, since these signatures can now be applied to neurological indications

tested in clinical studies with ANAVEX ® 2-73 including Alzheimer’s disease, Parkinson’s disease dementia

and Rett syndrome.

ANAVEX ® 2-73

data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study.

On July 2, 2018,

the Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled

On July 2, 2018, the

Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled

48-week safety and efficacy trial of ANAVEX ® 2-73 for the treatment of early Alzheimer’s disease.

trial sites in Canada, the United Kingdom, the Netherlands and Germany were also added.

This Phase 2b/3 study design incorporates inclusion of

genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a study.

The Phase 2b/3 study, which

is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different ANAVEX ® 2-73 doses or

placebo, commenced in October 2018.

data also validates ANAVEX ® 2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer’s

disease, Parkinson’s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman

syndrome, multiple sclerosis and, more recently, tuberous sclerosis complex (TSC).

ANAVEX ® 2-73 demonstrated significant

improvements in all of these indications in the respective preclinical animal models.

a study sponsored by the Foundation for Angelman Syndrome, ANAVEX ® 2-73 was assessed in a mouse model for the development

of audiogenic seizures.

The results indicated that ANAVEX ® 2-73 administration significantly reduced audiogenic-induced

In a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX ® 2-73

restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels.

BDNF under-expression has been observed

in many neurodevelopmental and neurodegenerative pathologies.

BDNF signaling promotes maturation of both excitatory and inhibitory

ANAVEX ® 2-73 normalization of BDNF expression could be a contributing factor for the positive data observed

in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.

data presented also indicates that ANAVEX ® 2-73 demonstrates protective effects of mitochondrial enzyme complexes

during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental

data on ANAVEX ® 2-73 related to multiple sclerosis indicates that ANAVEX ® 2-73 may promote remyelination

in multiple sclerosis disease.

Further, data also demonstrates that ANAVEX ® 2-73 provides protection for oligodendrocytes

(“OL’s”) and oligodendrocyte precursor cells (“OPC’s”), as well as central nervous system

neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.

March 2018, we presented preclinical data of ANAVEX ® 2-73 in a genetic mouse model of tuberous sclerosis complex

TSC is a rare genetic disorder characterized by the growth of numerous benign tumors in many parts of the

body with a high incidence of seizures.

The new preclinical data demonstrates that treatment with ANAVEX ® 2-73 significantly

increases survival and reduces seizures.

ANAVEX ® 3-71

is a clinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation,

which has been shown to enhance neuroprotection and cognition in Alzheimer’s disease models.

ANAVEX ® 3-71

is a CNS-penetrable potential disease modifying treatment for cognitive impairments.

It is highly effective in very small doses

against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies,

and also has beneficial effects on inflammation and mitochondrial dysfunctions.

ANAVEX ® 3-71 indicates extensive

therapeutic advantages in Alzheimer’s and other protein-aggregation-related diseases given its ability to enhance neuroprotection

and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.

preclinical study examined the response of ANAVEX ® 3-71 in aged transgenic animal models and showed a significant

reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71.

April 2016, the FDA granted Orphan Drug Designation to ANAVEX ® 3-71 for the treatment of Frontotemporal dementia

pathological conditions ANAVEX ® 3-71 demonstrated the formation of new synapses between neurons (synaptogenesis)

without causing an abnormal increase in the number of astrocytes.

In neurodegenerative diseases such as Alzheimer’s and

Parkinson’s disease, synaptogenesis is believed to be impaired.

Additional preclinical data presented also indicates that

in addition to reducing oxidative stress, ANAVEX ® 3-71 demonstrates protective effects of mitochondrial enzyme complexes

during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental

July 2020, we commenced the first Phase 1 clinical trial of ANAVEX ® 3-71, with focus on the treatment of Frontotemporal

Dementia (FTD) and other dementia indications with unmet medical need .

is more fully described above under Clinical Studies Overview – Frontotemporal Dementia .

ANAVEX ® 1-41

This Phase 2b/3 study design incorporates

inclusion of genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a study.

The Phase 2b/3

study, which has completed enrollment, randomized 1:1:1 to either two different ANAVEX ® 2-73 doses or placebo, commenced

in October 2018.

Preclinical data also validates ANAVEX ® 2-73

as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer’s disease, Parkinson’s disease

or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis and,

more recently, tuberous sclerosis complex (TSC).

ANAVEX ® 2-73 demonstrated significant improvements in all of these

indications in the respective preclinical animal models.

In a study sponsored by the Foundation for

Angelman Syndrome, ANAVEX ® 2-73 was assessed in a mouse model for the development of audiogenic seizures.

indicated that ANAVEX ® 2-73 administration significantly reduced audiogenic-induced seizures.

In a study sponsored

by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX ® 2-73 restored hippocampal

brain-derived neurotrophic factor (BDNF) expression to normal levels.

BDNF under-expression has been observed in many neurodevelopmental

and neurodegenerative pathologies.

BDNF signaling promotes maturation of both excitatory and inhibitory synapses.

ANAVEX ® 2-73

is a sigma-1 receptor agonist.

Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from

degeneration or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and

impairs cell viability.

In addition, in animal models, ANAVEX ® 1-41 prevented the expression of caspase-3, an enzyme

that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates

learning, emotion and memory.

These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism

data presented also indicates that ANAVEX ® 1-41 demonstrates protective effects of mitochondrial enzyme complexes

during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental

normalization of BDNF expression could be a contributing factor for the positive data observed in both neurodevelopmental and neurodegenerative

disorders like Angelman and Fragile X syndromes.

Preclinical data presented also indicates that

ANAVEX ® 2-73 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which,

if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

Preclinical data on ANAVEX ® 2-73

related to multiple sclerosis indicates that ANAVEX ® 2-73 may promote remyelination in multiple sclerosis disease.

Further, data also demonstrates that ANAVEX ® 2-73 provides protection for oligodendrocytes (“OL’s”)

and oligodendrocyte precursor cells (“OPC’s”), as well as central nervous system neurons in addition to helping

repair by increasing OPC proliferation and maturation in tissue culture.

In March 2018, we presented preclinical data

of ANAVEX ® 2-73 in a genetic mouse model of tuberous sclerosis complex (“TSC”).

TSC is a rare genetic

disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures.

new preclinical data demonstrates that treatment with ANAVEX ® 2-73 significantly increases survival and reduces seizures.

ANAVEX ® 3-71

ANAVEX ® 3-71 is a clinical drug

candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has been

shown to enhance neuroprotection and cognition in Alzheimer’s disease models.

ANAVEX ® 3-71 is a CNS-penetrable

potential disease modifying treatment for cognitive impairments.

It is highly effective in very small doses against the major Alzheimer’s

hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects

on inflammation and mitochondrial dysfunctions.

ANAVEX ® 3-71 indicates extensive therapeutic advantages in Alzheimer’s

and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor

activation and M1 muscarinic allosteric modulation.

A preclinical study examined the response of

ANAVEX ® 3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,

amyloid beta pathology and inflammation with the administration of ANAVEX 3-71.

In April 2016, the FDA granted Orphan Drug Designation

to ANAVEX ® 3-71 for the treatment of Frontotemporal dementia (FTD).

During pathological conditions ANAVEX ® 3-71

demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number

of astrocytes.

In neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, synaptogenesis is believed

to be impaired.

Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX ® 3-71

demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed

to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

In July 2020, we commenced the first Phase

1 clinical trial of ANAVEX ® 3-71, with focus on the treatment of Frontotemporal Dementia (FTD) and other

dementia indications with unmet medical need .

The study is more fully described above under Clinical Studies Overview

– Frontotemporal Dementia .

ANAVEX ® 1-41

a mixed sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain.

ANAVEX ® 1-41 is a sigma-1 receptor

Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death)

through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability.

In addition, in animal models, ANAVEX ® 1-41 prevented the expression of caspase-3, an enzyme that plays a key role

in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion

These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.

Preclinical data presented also indicates that

ANAVEX ® 1-41 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which,

if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

ANAVEX ® 1066

was tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats.

ANAVEX ® 1066, a mixed

sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain.

ANAVEX ® 1066 was

tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats.

In the chronic

8 unchanged sentences

ANAVEX ® 1037

is designed for the treatment of prostate and pancreatic cancer.

It is a low molecular weight, synthetic compound exhibiting high

affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar

In advanced pre-clinical studies, this compound revealed antitumor potential.

It has also been shown to selectively kill

human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient

Scientific publications highlight the possibility that these ligands may stop tumor growth and induce selective cell

death in various tumor cell lines.

ANAVEX ® 1037 is designed for

the treatment of prostate and pancreatic cancer.

It is a low molecular weight, synthetic compound exhibiting high affinity for

sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels.

advanced pre-clinical studies, this compound revealed antitumor potential.

It has also been shown to selectively kill human cancer

cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models.

publications highlight the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor

Sigma receptors are highly expressed in different tumor cell types.

Binding by appropriate

sigma-1 and/or sigma-2 ligands can induce selective apoptosis.

In addition, through tumor cell membrane reorganization and interactions

with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer

cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.

compounds are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated

in pre-clinical models will be shown in human testing.

continue to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our

programs and realize maximum shareholder value.

Further, we may acquire or develop new intellectual property and assign, license,

or otherwise transfer our intellectual property to further our goals.

Target Indications

have developed compounds with potential application to two broad categories and several specific indications.

Nervous System Diseases

disease – In 2020, an estimated 5.8 million Americans were suffering from Alzheimer’s disease.

The Alzheimer’s

Association ® estimates that by 2050, this number will rise to nearly 14 million Americans.

Medications on the market

today treat only the symptoms of Alzheimer’s disease and do not have the ability to stop its onset or its progression.

is an urgent and unmet need for both a disease modifying cure for Alzheimer’s disease as well as for better symptomatic

disease – Parkinson’s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity,

and slow, imprecise movement.

It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter

Parkinson’s disease afflicts more than 10 million people worldwide, typically middle-aged and elderly people.

The Parkinson’s disease market is expected to expand to $3.2 billion by 2021, according to business intelligence provider

GBI Research.

syndrome - Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain develops,

including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis.

It is considered

a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene.

Because males have a different

chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating ways.

Most of them die

before birth or in early infancy.

For females who survive infancy, Rett syndrome leads to severe impairments, affecting nearly

every aspect of the child’s life;

severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures

and even the ability to breathe easily.

Binding by appropriate sigma-1 and/or sigma-2 ligands

can induce selective apoptosis.

In addition, through tumor cell membrane reorganization and interactions with ion channels, our

drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original

site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.

Our compounds are in the pre-clinical and clinical

testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown in

human testing.

We continue to identify and initiate discussions

with potential strategic and commercial partners to most effectively advance our programs and realize maximum shareholder value.

Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property

to further our goals.

Our Target Indications

We have developed compounds with potential

application to two broad categories and several specific indications.

Central Nervous System Diseases

Alzheimer’s disease – In 2021, an estimated 5.7 million

Americans were suffering from Alzheimer’s disease.

The Alzheimer’s Association ® estimates that by 2050,

this number will rise to nearly 14 million Americans.

Medications on the market today treat only the symptoms of Alzheimer’s

disease and do not have the ability to stop its onset or its progression.

There is an urgent and unmet need for both a disease

modifying cure for Alzheimer’s disease as well as for better symptomatic treatments.

Parkinson’s disease – Parkinson’s disease is a progressive

disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement.

It is associated with degeneration

of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine.

Parkinson’s disease afflicts more than

10 million people worldwide, typically middle-aged and elderly people.

The Parkinson’s disease market is expected to expand

to $11.5 billion by 2029, according to business intelligence provider GBI Research.

Rett syndrome – Rett syndrome is a rare X-linked genetic neurological

and developmental disorder that affects the way the brain develops, including protein transcription, which is altered and as a

result lead to severe disruptions in neuronal homeostasis.

It is considered a rare, progressive neurodevelopmental disorder and

is caused by a single mutation in the MECP2 gene.

Because males have a different chromosome combination from females, boys who

have the genetic MECP2 mutation are affected in devastating ways.

Most of them die before birth or in early infancy.

who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child’s life;

mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily.

Rett syndrome affects approximately 1 in every 10,000-15,000 females.

- Depression is a major cause of morbidity worldwide according to the World Health Organization.

Pharmaceutical treatment for

depression is dominated by blockbuster brands, with the leading nine brands historically accounting for approximately 75% of total

However, the dominance of the leading brands is waning, largely due to the effects of patent expiration and generic competition .

- Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures.

These seizures are transient

signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain.

According to the Centers for Disease

Control and Prevention, in 2015 epilepsy affected 3.4 million Americans.

Today, epilepsy is often controlled, but not cured, with

medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs.

Because epilepsy

afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs

and second generation anti-epileptic drugs .

Pain – We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any

part of the body.

Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal

pain medications.

Special medications have become more specific to neuralgia and typically fall under the category of membrane

stabilizing drugs or antidepressants .

Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye.

melanoma accounts for 75% of all deaths associated with skin cancer.

The treatment includes surgical removal of the tumor, adjuvant

treatment, chemo and immunotherapy, or radiation therapy.

According to IMS Health the worldwide malignant melanoma market is expected

to grow to $4.4 billion by 2022.

Cancer – Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive

The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes.

Drug therapeutics for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.

Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas.

In the United States, approximately 55,000 new cases of pancreatic

cancer will be diagnosed this year and approximately 44,000 patients will die as a result of their cancer, according to the American

Cancer Society.

Sales predictions by GBI Research forecast that the market for the pharmaceutical treatment of pancreatic cancer

in the United States and five largest European countries will increase to $2.9 billion by 2021 .

pharmaceutical industry is intensely competitive.

this time, our competitors are other biomedical development companies that are trying to discover and develop compounds to be

used in the treatment of Alzheimer’s disease and other CNS diseases, and those companies already doing so.

Those companies

include Biogen (NASDAQ:BIIB), Pfizer Inc.

(NYSE:PFE), Abbvie Plc (NYSE:ABBV), Novartis AG (NYSE:NVS), GlaxoSmithKline Plc (NYSE:GSK),

(NYSE:MRK), Eli Lilly & Co.

LLY), Johnson & Johnson (NYSE:JNJ) and Roche Holding AG (VTX:ROG).

For additional discussion of the risks related to competition, see Item 1A “Risk Factors.”

Trademarks and Intellectual Property

hold ownership or exclusive rights to nine U.S.

patents, ten U.S.

Depression – Depression is a major cause of morbidity worldwide

according to the World Health Organization.

Pharmaceutical treatment for depression is dominated by blockbuster brands, with the

leading nine brands historically accounting for approximately 75% of total sales.

However, the dominance of the leading brands

is waning, largely due to the effects of patent expiration and generic competition.

Epilepsy – Epilepsy is a common chronic neurological disorder

characterized by recurrent unprovoked seizures.

These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous

neuronal activity in the brain.

According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million

Today, epilepsy is often controlled, but not cured, with medication that is categorized as older traditional anti-epileptic

drugs and second generation anti-epileptic drugs.

Because epilepsy afflicts sufferers in different ways, there is a need for drugs

used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.

Neuropathic Pain – We define neuralgia, or neuropathic pain,

as pain that is not related to activation of pain receptor cells in any part of the body.

Neuralgia is more difficult to treat

than some other types of pain because it does not respond well to normal pain medications.

Special medications have become more

specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.

Malignant Melanoma – Predominantly a skin cancer, malignant melanoma

can also occur in melanocytes found in the bowel and the eye.

Malignant melanoma accounts for 75% of all deaths associated with

The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy.

According to iHealthcareAnalyst, Inc.

the worldwide malignant melanoma market is expected to grow to $6.4 billion by 2027.

Prostate Cancer – Specific to men, prostate cancer is a form

of cancer that develops in the prostate, a gland in the male reproductive system.

The cancer cells may metastasize from the prostate

to other parts of the body, particularly the bones and lymph nodes.

Drug therapeutics for prostate cancer are expected to increase

to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.

Pancreatic Cancer – Pancreatic cancer is a malignant neoplasm

of the pancreas.

In the United States, approximately 55,000 new cases of pancreatic cancer will be diagnosed this year and approximately

44,000 patients will die as a result of their cancer, according to the American Cancer Society.

Sales predictions by FutureWise

forecast that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $4.7 billion by 2027.

The drug discovery and development industry

is very competitive, characterized by rapid advancements in technology, where protection of proprietary advancements is essential.

Any product candidates that we may successfully develop and commercialize, may compete with existing therapies, or new therapies

that may become available in the future.

Our commercial opportunities could be reduced or eliminated if our competitors develop

and commercialize products that are more effective, have fewer side effects, are more convenient or are less expensive than any

products that we may develop.

Our approach to the treatment of Alzheimer’s

disease and other CNS diseases differs from our competitors.

Our platform may offer a disease-modifying approach in neurodegenerative

and neurodevelopmental diseases by activation of sigma-1 receptors.

When activated by SIGMAR1 agonists, such as ANAVEX ® 2-73,

SIGMAR1 reduces cellular stress before and after RNA gene transcription.

Studies confirm the predictive biomarker of response established

through SIGMAR1 mRNA expression.

Because of its role in maintaining neuronal homeostasis, sigma receptors show significant promise

as viable targets for therapeutic molecules in an effort to treat Alzheimer’s disease and other CNS diseases and disorders,

including Parkinson’s disease and Rett syndrome, by restoring healthy gene expression.

At this time, our competitors are primarily

other biomedical development companies that are aiming to discover and develop compounds to be used in the treatment of Alzheimer’s

disease and other CNS diseases, and those companies already doing so.

We also face competition from academic institutions and government

agencies, both in the United States and abroad.

Our competitors may have significantly

greater financial resources, an established presence in the market, expertise in research and development, manufacturing, preclinical

and clinical testing, may be in the process of obtaining regulatory approvals and marketing of approved products.

These competitors

also compete with us in recruiting and retaining qualified scientific and technical personnel, establishing clinical study sites

and patient registration for clinical studies, as well as in acquiring or developing technologies complementary to, or necessary

for, our programs.

Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative

arrangements with large and established companies.

For additional discussion of the risks

related to competition, see Item 1A “Risk Factors.”

Patents, Trademarks and Intellectual

We hold ownership or exclusive rights

to fifteen U.S.

patents, sixteen U.S.

patent applications, and various PCT or ex-U.S.

patent applications

relating to our drug candidates, methods associated therewith, and to our research programs.

own one issued U.S.

patent entitled “ANAVEX ® 2-73 and certain anticholinesterase inhibitors composition and

method for neuroprotection” claims a composition of matter of ANAVEX ® 2-73 directed to a novel and synergistic

neuroprotective compound combined with donepezil and other cholinesterase inhibitors.

This patent is expected to expire

in June 2034, absent any patent term extension for regulatory delays.

We own two issued U.S.

patents each with claims directed

to crystalline forms of ANAVEX ® 2-73.

The first of these two patents claims crystalline forms of ANAVEX ® 2-73,

dosage forms and compositions containing crystalline ANAVEX ® 2-73, and methods of treatment for Alzheimer’s

disease using them.

This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays.

second of these two patents claims pharmaceutical compositions containing a crystalline form of ANAVEX ® 2-73, and

methods of treatment for Alzheimer’s disease using the compositions.

This patent is expected to expire in June 2037, absent

any patent term extension for regulatory delays.

We also own an issued U.S.

patent that claims methods and dosage forms for treating

seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either:

(i) ANAVEX ® 2-73 and its

active metabolite ANAVEX ® 19-144;

or (ii) ANAVEX ® 19-144.

This patent is expected to expire in October

2035, absent any patent term extension for regulatory delays.

We also own an issued U.S.

patent that claims methods for treating

a neurodevelopmental disorder or multiple sclerosis by administering ANAVEX ® 2-73, ANAVEX ® 19-144,

and/or ANAVEX ® 1-41, another sigma receptor ligand similar to ANAVEX ® 2-73.

patent applications relating to our drug

candidates, methods associated therewith, and to our research programs.

We own one issued U.S.

patent entitled

“ANAVEX ® 2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection” claims

a composition of matter of ANAVEX ® 2-73 directed to a novel and synergistic neuroprotective compound combined with

donepezil and other cholinesterase inhibitors.

This patent is expected to expire in June 2034, absent any patent term extension

for regulatory delays.

We own three issued U.S.

patents each with claims directed to crystalline forms of ANAVEX ® 2-73.

The first of these three patents claims crystalline forms of ANAVEX ® 2-73, dosage forms and compositions containing

crystalline ANAVEX ® 2-73, and methods of treatment for Alzheimer’s disease using them.

This patent is expected

to expire in January 2037, absent any patent term extension for regulatory delays.

to expire in July 2036, absent any patent term extension for regulatory delays.

The second of these three patents claims pharmaceutical

compositions containing a crystalline form of ANAVEX ® 2-73, and methods of treatment for Alzheimer’s disease

using the compositions.

This patent is expected to expire in June 2037, absent any patent term extension for regulatory delays.

The third of these three patents claims pharmaceutical compositions containing a crystalline form of ANAVEX ® 2-73,

and methods of treatment for Alzheimer’s disease using the compositions.

This patent is expected to expire in June 2037,

absent any patent term extension for regulatory delays.

We also own two issued U.S.

patents for seizure treatment.

these two patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug

combined with either:

(i) ANAVEX ® 2-73 and its active metabolite ANAVEX ® 19-144;

or (ii) ANAVEX ® 19-144.

The second of these two patents further claims a combination seizure treatment involving administration of an anti-epilepsy drug

combined with (i) ANAVEX ® 19-144, or (ii) ANAVEX 19-144 ® and ANAVEX 2-73 ® .

are expected to expire in October 2035, absent any patent term extension for regulatory delays.

We also own two issued U.S.

with claims directed to treating neurodevelopmental disorders.

These patents claim methods for treating a neurodevelopmental disorder

or multiple sclerosis by administering ANAVEX ® 2-73, ANAVEX ® 19-144, and/or ANAVEX ® 1-41

(another sigma receptor ligand similar to ANAVEX ® 2-73), or compositions thereof.

Both patents are expected to expire

in January 2037, absent any patent term extension for regulatory delays.

In addition, we own one issued U.S.

with claims directed to methods of treating melanoma with a compound related to ANAVEX ® 2-73.

This patent is expected

to expire in February 2030, absent any patent term extension for regulatory delays.

also own one issued patent with claims directed to methods for treating or preventing pain with ANAVEX ® 1066.

patent is expected to expire in November 2036, absent any patent term extension for regulatory delays.

ANAVEX ® 2-73, ANAVEX ® 19-144, ANAVEX ® 1-41, and ANAVEX ® 1066, we also

have granted or pending applications in Australia, Canada, China, Europe, Japan, and Hong Kong, and are expected to expire after

regard to ANAVEX ® 3-71, we own exclusive rights to two issued U.S.

patents with claims respectively directed to

the ANAVEX ® 3-71 compound and methods of treating various diseases including Alzheimer’s with the same.

patents are expected to expire in April 2030, and January 2030, respectively, absent any patent term extension for regulatory

We also own exclusive rights to related patents or applications that are granted or pending in Australia, Canada, China,

Europe, Japan, Korea, New Zealand, Russia, and South Africa, and are expected to expire in January 2030.

also own other patent applications directed to enantiomers, formulations and uses that may provide additional protection for one

or more of our product candidates.

regard patents and other intellectual property rights as corporate assets.

Accordingly, we attempt to optimize the value of intellectual

property in developing our business strategy including the selective development, protection, and exploitation of our intellectual

property rights.

In addition to filings made with intellectual property authorities, we protect our intellectual property and

confidential information by means of carefully considered processes of communication and the sharing of information, and by the

use of confidentiality and non-disclosure agreements and provisions for the same in contractor’s agreements.

While no agreement

offers absolute protection, such agreements provide some form of recourse in the event of disclosure, or anticipated disclosure.

intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical

questions for which important legal principles are unresolved.

For more information regarding challenges to our existing or future

patents, see Item 1A “Risk Factors.”

authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other

things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping,

promotion, advertising, distribution, marketing and export and import of products such as those we are developing.

must be approved by the FDA through the NDA process before it may be legally marketed in the United States.

We are subject to

various government regulations in connection with the development of our pipeline.

Patent with claims

directed to methods of treating melanoma with a compound related to ANAVEX ® 2-73.

This patent is expected to expire

in February 2030, absent any patent term extension for regulatory delays.

We also own an issued U.S.

patent that claims crystalline

forms of ANAVEX ® 19-144, dosage forms and compositions containing the crystalline forms of ANAVEX ® 19-144,

and methods of treatment for Alzheimer’s disease.

This patent is expected to expire in July 2036, absent any patent term

extension for regulatory delays.

Further, we own one issued U.S.

Patent with claims directed to methods of treating cardiac dysfunction

with ANAVEX ® 2-73 .

This patent is expected to expire in July 2038, absent any patent term extension for regulatory

We also own two issued U.S.

related to ANAVEX ® 1066.

The first of these two patents claims methods for treating or preventing pain using (+)

ANAVEX ® 1066 isomer.

The second patent claims methods for treating or preventing pain using (-) ANAVEX ® 1066

Both patents are expected to expire in November 2036, absent any patent term extension for regulatory delays.

For ANAVEX ® 2-73, ANAVEX ® 19-144,

ANAVEX ® 1-41, and ANAVEX ® 1066, we also have granted or pending applications in Australia, Canada,

China, Europe, Japan, and Hong Kong, which are expected to expire after 2035.

With regard to ANAVEX ® 3-71,

we own exclusive rights to two issued U.S.

patents with claims respectively directed to the ANAVEX ® 3-71 compound

and methods of treating various diseases including Alzheimer’s with the same.

These patents are expected to expire in April

2030, and January 2030, respectively, absent any patent term extension for regulatory delays.

We also own exclusive rights to related

patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and

South Africa, which are expected to expire in January 2030.

We also own other patent applications

directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for

one or more of our product candidates.

We regard patents and other intellectual

property rights as corporate assets.

Accordingly, we attempt to optimize the value of intellectual property in developing our business

strategy including the selective development, protection, and exploitation of our intellectual property rights.

In addition to

filings made with intellectual property authorities, we protect our intellectual property and confidential information by means

of carefully considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure

agreements and provisions for the same in contractor’s agreements.

While no agreement offers absolute protection, such agreements

provide some form of recourse in the event of disclosure, or anticipated disclosure.

Our intellectual property position,

like that of many biomedical companies, is uncertain and involves complex legal and technical questions for which important legal

principles are unresolved.

For more information regarding challenges to our existing or future patents, see “Risk Factors”.

Government regulation

Government authorities in the United

States, at the federal, state and local levels, and other countries extensively regulate, among other things, the research, development,

testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,

marketing and export and import of products such as those we are developing.

A new drug must be approved by the FDA through the

NDA process before it may be legally marketed in the United States.

We are subject to various government regulations in connection

with the development of our pipeline.

Drug Development and Regulation

the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act and its implementing regulations (“FDCA”).

The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign

statutes and regulations require the expenditure of substantial time and financial resources.

Failure to comply with the applicable

requirements at any time during the product development process, approval process or after approval may subject an applicant

to administrative or judicial sanctions.

These sanctions could include the FDA’s refusal to approve pending applications,

withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of

production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal

Any agency or judicial enforcement action could have a material adverse effect on us.

a drug candidate is identified for development, it enters the preclinical testing stage.

Preclinical tests include laboratory

evaluations of product chemistry, toxicity and formulation, as well as animal studies.

An Investigational New Drug application

(“IND”) sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical

data, to FDA as part of the IND.

The sponsor must also include a protocol detailing, among other things, the objectives of the

first phase of clinical trials, the parameters to be used in monitoring the safety of the trial, and the effectiveness criteria

to be evaluated should the first phase lend itself to an efficacy evaluation.

Some preclinical testing may continue even after

the IND is submitted.

The IND automatically becomes effective thirty (30) days after receipt by FDA, unless FDA, within the 30-day

time period, places the clinical trial on a clinical hold.

Clinical holds also may be imposed by the FDA at any time before or

during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements,

and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.

clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with FDA good clinical

practice (“GCP”) requirements, which include a requirement that all research subjects provide their informed consent

in writing for their participation in any clinical trial.

Clinical trials must be conducted under protocols detailing the objectives

of the trial, dosing procedures, subject selection and exclusion criteria and the safety and/or effectiveness criteria to be evaluated.

Each protocol must be submitted to FDA as part of the IND, and timely safety reports must be submitted to FDA and the investigators

for serious and unexpected adverse events.

An Institutional Review Board (“IRB”) at each institution participating

in the clinical trial must review and approve each protocol before a clinical trial may commence at the institution and must also

approve the information regarding the trial as well as the consent form that must be provided to each trial subject or his or

her legal representative, monitor the study until completed and otherwise comply with all applicable IRB regulations.

clinical trials are typically conducted in three sequential phases that may overlap or be combined in certain cases:

The compound is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism,

distribution and excretion and, if possible, to gain an early indication of its effectiveness.

In most cases, initial Phase 1

clinical trials are conducted with healthy volunteers.

However, where the compound being evaluated is for the treatment of severe

or life-threatening diseases, such as cancer, and especially when the product may be too toxic to ethically administer to healthy

volunteers, the initial human testing may be conducted on patients with the target disease or condition.

Sponsors sometimes subdivide

their Phase 1 clinical trials into Phase 1a and Phase 1b clinical trials.

Phase 1b clinical trials are typically aimed at confirming

dosage, pharmacokinetics and safety in a larger number of patients.

Some Phase 1b studies evaluate biomarkers or surrogate markers

that may be associated with efficacy in patients with specific types of diseases or conditions.

This phase involves clinical trials in a limited patient population to identify possible adverse effects and safety risks,

to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to confirm dosage tolerance

and appropriate dosage.

Phase 3 clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population,

generally at geographically dispersed clinical study sites.

These clinical trials, often referred to as “pivotal”

clinical trials, are intended to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate

basis for product labeling.

or the sponsor may suspend a clinical trial at any time on various grounds, including any finding that the research subjects or

patients are being exposed to an unacceptable health risk.

Similarly, an IRB can suspend or terminate approval of a clinical trial

at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug

has been associated with unexpected, serious harm to study subjects.

In addition, clinical trials may be overseen by an independent

group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee.

Depending on its charter,

this committee may determine whether a trial may move forward at designated check points based on access to certain data from

Post-approval

trials may also be conducted after a drug receives initial marketing approval.

These trials, often referred to as “Phase

4” trials, are used to gain additional experience from the treatment of patients in the intended therapeutic indication.

In certain instances, FDA may mandate the performance of such clinical trials as a condition of approval of an NDA.

the development of a new drug, sponsors are given several opportunities to meet with FDA.

These meetings can provide an opportunity

for the sponsor to share information about the progress of the application or clinical trials, for the FDA to provide advice,

and for the sponsor and the FDA to reach agreement on the next phase of development.

These meetings may occur prior to the submission

of an IND, at the end of Phase 2 clinical trials, or before an NDA is ultimately submitted.

Sponsors typically use the meetings

at the end of the Phase 2 trials to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials

that they believe will support approval of the new drug.

In the United States, the FDA regulates drugs

under the federal Food, Drug, and Cosmetic Act and its implementing regulations (“FDCA”).

The process of obtaining

regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations

require the expenditure of substantial time and financial resources.

Failure to comply with the applicable U.S.

requirements at

any time during the product development process, approval process or after approval may subject an applicant to administrative

or judicial sanctions.

These sanctions could include the FDA’s refusal to approve pending applications, withdrawal of an

approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution,

injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.

Any agency or judicial

enforcement action could have a material adverse effect on us.

Once a drug candidate is identified for development,

it enters the preclinical testing stage.

Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation,

as well as other preclinical studies.

An Investigational New Drug application (“IND”) sponsor must submit the results

of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND.

must also include a protocol detailing, among other things, the objectives of the first phase of clinical trials, the parameters

to be used in monitoring the safety of the trial, and the effectiveness criteria to be evaluated should the first phase lend itself

to an efficacy evaluation.

Some preclinical testing may continue even after the IND is filed.

The IND automatically becomes effective

thirty (30) days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical

Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about ongoing

or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the

FDA notifies the sponsor that the hold has been lifted.

All clinical trials must be conducted under

the supervision of one or more qualified investigators in accordance with FDA good clinical practice (“GCP”) requirements,

which include a requirement that all research subjects provide their informed consent in writing for their participation in any

clinical trial.

Clinical trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject

selection inclusion and exclusion criteria and the safety and/or effectiveness criteria to be evaluated.

Each protocol must be

submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and the investigators for serious

and unexpected adverse events.

An Institutional Review Board (“IRB”) at each institution participating in the clinical

trial must review and approve each protocol before a clinical trial may commence at the institution and must also approve the information

regarding the trial as well as the consent form that must be provided to each trial participant or his or her legal representative,

monitor the study until completed and otherwise comply with all applicable IRB regulations.

Human clinical trials are typically conducted

in three sequential phases that may overlap or be combined in certain cases:

The compound is initially introduced

into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if

possible, to gain an early indication of its effectiveness.

In most cases, initial Phase 1 clinical trials are conducted with healthy

However, where the compound being evaluated is for the treatment of severe or life-threatening diseases, such as cancer,

and especially when the product may be too toxic to ethically administer to healthy volunteers, the initial human testing may be

conducted on patients with the target disease or condition.

Sponsors sometimes subdivide their Phase 1 clinical trials into Phase

1a and Phase 1b clinical trials.

Phase 1b clinical trials are typically aimed at confirming dosage, pharmacokinetics and safety

in a larger number of patients.

Some Phase 1b studies evaluate biomarkers or surrogate markers that may be associated with efficacy

in patients with specific types of diseases or conditions.

This phase involves clinical trials

in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of

the product for specific targeted diseases or conditions and to confirm dosage tolerance and appropriate dosage.

Phase 3 clinical trials are undertaken

to further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed

clinical study sites.

These clinical trials, often referred to as “pivotal” or “confirmatory” clinical

trials, are intended to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate basis

for product labeling.

The FDA or the sponsor may suspend a clinical

trial at any time on various grounds, including any finding that the research subjects or patients are being exposed to an unacceptable

Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is

not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected, serious

harm to study subjects.

In addition, clinical trials may be overseen by an independent group of qualified experts organized by

the sponsor, known as a data safety monitoring board or committee.

Depending on its charter, this committee may determine whether

a trial may move forward at designated check points based on access to certain data from the trial.

Phase 4 or post-approval trials may

also be conducted after a drug receives initial marketing approval.

These trials, often referred to as “Phase 4” trials,

are used to gain additional experience from the treatment of patients in the intended therapeutic indication.

In certain instances,

the FDA may mandate the performance of such clinical trials as a condition of approval of an NDA.

During the development of a new drug, sponsors

are given several opportunities to meet with the FDA.

These meetings can provide an opportunity for the sponsor to share information

about the progress of the application or clinical trials, for the FDA to provide advice, and for the sponsor and the FDA to reach

agreement on the next phase of development.

These meetings may occur prior to the submission of an IND, at the end of Phase 2 clinical

trials, or before an NDA is ultimately submitted.

Sponsors typically use the meetings at the end of the Phase 2 trials to discuss

Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the

Meetings at other times may be made upon request.

with clinical trials, companies typically complete additional, animal or other non-clinical studies, develop additional information

about the chemistry and physical characteristics of the drug, and finalize a process for manufacturing the product in commercial

quantities in accordance with FDA’s current Good Manufacturing Practices (“cGMP”) requirements.

The manufacturing

process must consistently produce quality batches of the drug and, among other things, the manufacturer must develop methods for

testing the identity, strength, quality and purity of the final drug.

In addition, appropriate packaging must be selected and

tested, and stability studies must be conducted to demonstrate the effectiveness of the packaging and that the compound does not

undergo unacceptable deterioration over its shelf life.

the IND is active, progress reports summarizing the results of ongoing clinical trials and nonclinical studies performed since

the last progress report must be submitted on at least an annual basis to FDA, and written IND safety reports must be submitted

to FDA and investigators for serious and unexpected adverse events, findings from other studies suggesting a significant risk

to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans,

and any clinically important, increased incidence of a serious adverse reaction compared to that listed in the protocol or investigator

are also requirements governing the submission of certain clinical trials and completed trial results to public registries.

of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial registration

and results information, which is made publicly available at www.clinicaltrials.gov.

Failure to properly report clinical trial

results can result in civil monetary penalties.

Disclosure of clinical trial results can often be delayed until the new product

or new indication being studied has been approved.

Concurrent with clinical trials, companies

typically complete additional, animal or other non-clinical studies, develop additional information about the chemistry and physical

characteristics of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with the

FDA’s current Good Manufacturing Practices (“cGMP”) requirements.

The manufacturing process must consistently

produce quality batches of the drug and, among other things, the manufacturer must develop methods for testing the identity, strength,

quality and purity of the final drug.

In addition, appropriate packaging must be selected and tested, and stability studies must

be conducted to demonstrate the effectiveness of the packaging and that the compound does not undergo unacceptable deterioration

over its shelf life.

While the IND is active, progress reports summarizing

the results of ongoing clinical trials and nonclinical studies performed since the last progress report must be submitted on at

least an annual basis to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and

unexpected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs,

findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important, increased incidence

of a serious adverse reaction compared to that listed in the protocol or investigator brochure.

There are also requirements governing the submission

of certain clinical trials and completed trial results to public registries.

Sponsors of certain clinical trials of FDA-regulated

products are required to register and disclose specified clinical trial registration and results information, which is made publicly

available at www.clinicaltrials.gov.

Failure to properly report clinical trial results can result in civil monetary penalties.

Disclosure of clinical trial results can often be delayed until the new product or new indication being studied has been approved.

review and approval process

results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the

manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information

are submitted to FDA as part of a New Drug Application (“NDA”).

The submission of an NDA is subject to the payment

of substantial user fees;

a waiver of which may be obtained under certain limited circumstances.

reviews NDAs to determine, among other things, whether the product is safe and effective for its intended use and whether it is

manufactured in a cGMP-compliant manner, which will assure and preserve the product’s identity, strength, quality and purity.

Under the Prescription Drug User Fee Act (“PDUFA”), FDA has a goal of ten months from the date of “filing”

of a standard, completed NDA for a new molecular entity to review and act on the submission.

This review typically takes twelve

months from the date the NDA is submitted to FDA because FDA has approximately two months to make a “filing” decision

after the application is submitted.

FDA conducts a preliminary review of all NDAs within the first sixty days after submission,

before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review.

FDA may request

additional information rather than accept an NDA for filing.

The results of product development, preclinical

and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted

on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a New Drug Application

The submission of an NDA is subject to the payment of substantial user fees;

a waiver of which may be obtained

under certain limited circumstances.

The FDA reviews NDAs to determine, among other

things, whether the product is safe and effective for its intended use and whether it is manufactured in a cGMP-compliant manner,

which will assure and preserve the product’s identity, strength, quality and purity.

Under the Prescription Drug User Fee

Act (“PDUFA”), the FDA has a goal of ten months from the date of “filing” of a standard, completed NDA

for a new molecular entity to review and act on the submission.

This review typically takes twelve months from the date the NDA

is submitted to the FDA because the FDA has approximately two months to make a “filing” decision after the application

is submitted.

The FDA conducts a preliminary review of all NDAs within the first sixty days after submission, before accepting

them for filing, to determine whether they are sufficiently complete to permit substantive review.

The FDA may request additional

information rather than accept an NDA for filing.

In this event, the NDA must be resubmitted with the additional information.

The resubmitted application also is subject to review before the FDA accepts it for filing.

may refer an application for a new drug to an advisory committee within FDA.

An advisory committee is a panel of independent experts,

including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether and under

what conditions the application should be approved.

FDA is not bound by the recommendations of such an advisory committee, but

it considers advisory committee recommendations carefully when making decisions.

approving an NDA, FDA will also inspect the facility where the product is manufactured.

FDA will not approve an application unless

it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure

consistent production of the product within required specifications.

Before approving an NDA, FDA may also inspect one or more

clinical trial sites to assure compliance with GCP requirements.

the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter.

A Complete Response Letter indicates

that the review cycle of the application is complete, and the application will not be approved in its present form.

Response Letter usually describes the specific deficiencies in the NDA identified by FDA and may require additional clinical data,

such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical

studies or manufacturing.

If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies

identified in the letter, or withdraw the application.

Even if such data and information are submitted, FDA may decide that the

NDA does not satisfy the criteria for approval.

An approval letter authorizes commercial marketing of the drug with prescribing

information for specific indications.

Pediatric Research Equity Act (“PREA”), requires IND sponsors to conduct pediatric clinical trials for most drugs,

for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration.

Under PREA, original

NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver.

The required assessment

must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations

and support dosing and administration for each pediatric subpopulation for which the product is safe and effective.

or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations.

A deferral may be

granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical

trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials

FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current

or fails to submit a request for approval of a pediatric formulation.

a drug receives FDA approval, the approval may be limited to specific diseases and dosages, which could restrict the commercial

value of the product.

In addition, FDA may require testing and surveillance programs to monitor the safety of approved products

which have been commercialized, and may require a sponsor to conduct post-marketing clinical trials, which are designed to further

assess a drug’s safety and effectiveness after NDA approval.

FDA may also place other conditions on approval, including

a requirement for a risk evaluation and mitigation strategy (“REMS”) to assure the safe use of the drug.

If FDA concludes

a REMS is needed, the sponsor of the NDA must submit a proposed REMS.

FDA will not approve the NDA without an approved REMS, if

A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted

distribution methods, patient registries and other risk minimization tools.

Any of these limitations on approval or marketing

could restrict the commercial promotion, distribution, prescribing or dispensing of products.

Marketing approval may be withdrawn

for non-compliance with REMS or other regulatory requirements, or if problems occur following initial marketing.

Post-approval

an approval is granted, FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems

occur after the drug reaches the market.

Later discovery of previously unknown problems with a drug may result in restrictions

on the drug or even complete withdrawal of the drug from the market.

After approval, some types of changes to the approved drug,

such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review

and approval.

Manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to

register their establishments with FDA and certain state agencies and are subject to periodic unannounced inspections by FDA and

certain state agencies for compliance with cGMP regulations and other laws and regulations.

drug product manufactured or distributed by us pursuant to FDA approval will be subject to continuing regulation by FDA, including,

among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing FDA with updated safety

and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature

requirements, and complying with FDA promotion and advertising requirements.

FDA strictly regulates labeling, advertising, promotion

and other types of information regarding approved drugs that are placed on the market, and imposes requirements and restrictions

on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses

or in patient populations that are not described in the product’s approved labeling (known as “off-label use”),

industry-sponsored scientific and educational activities, and promotional activities involving the internet.

Discovery of previously

unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing

of a product for a certain indication or withdrawal of the product from the market as well as possible civil or criminal sanctions.

Failure to comply with the applicable governmental requirements at any time during the product development process, approval process

or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse

FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing

clinical trials, enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution,

injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment,

restitution, disgorgement of profits, or civil or criminal penalties.

development and review programs

FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products

that meet certain criteria.

Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious

or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition.

With regard to a fast track product, FDA may consider for review sections of the NDA on a rolling basis before the complete application

is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, FDA agrees to accept sections

of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the

first section of the NDA.

product submitted to FDA for approval, including a product with a fast track designation, may also be eligible for other types

of FDA programs intended to expedite development and review, such as priority review and accelerated approval.

product is eligible for priority review if it is intended to treat a serious condition, and if approved, would provide a significant

improvement in safety or efficacy compared to currently marketed products.

FDA will attempt to direct additional resources to

the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review.

FDA endeavors

to review applications with priority review designations within six months of the filing date, as compared to ten months for review

of NDAs under its current PDUFA review goals.

addition, a product may be eligible for accelerated approval.

Drugs intended to treat serious or life-threatening diseases or

conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint

that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible

morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical

benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative

As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate

and well-controlled post-marketing clinical trials.

Drugs receiving accelerated approval may be subject to expedited withdrawal

procedures if the sponsor fails to conduct the required post-marketing trials or if such trials fail to verify the predicted clinical

In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials,

which could adversely impact the timing of the commercial launch of the product.

Food and Drug Administration Safety and Innovation Act (“FDASIA”) established a category of drugs referred to as “breakthrough

therapies” that may be eligible to receive breakthrough therapy designation.

A sponsor may seek FDA designation of a compound

as a “breakthrough therapy” if the product is intended, alone or in combination with one or more other products, to

treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate

substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment

effects observed early in clinical development.

The designation includes all of the fast track program features, as well as more

intensive FDA interaction and guidance.

The breakthrough therapy designation is a distinct status from both accelerated approval

and priority review, which can also be granted to the same drug if relevant criteria are met.

If a product is designated as breakthrough

therapy, FDA will work to expedite the development and review of such drug.

track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite

the development or approval process.

However, even if a product qualifies for one or more of these programs, FDA may later decide

that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will

not be shortened.

drug designation

the Orphan Drug Act, FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease

or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals

in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the

United States for this type of disease or condition will be recovered from sales of the product.

Orphan designation must be requested

before an NDA is submitted.

After FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan

use are publicly disclosed by FDA.

Orphan designation does not convey any advantage in or shorten the duration of the regulatory

review and approval process.

a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has

such designation, the product is entitled to orphan product exclusivity, which means that FDA may not approve any other applications

to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical

superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities.

The designation

of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs,

tax advantages and user-fee waivers.

However, competitors, may receive approval of different products for the indication for which

the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan

product has exclusivity.

Orphan exclusivity also could block the approval of one of our compounds for seven years if our compound

is determined to be contained within the competitor’s product for the same indication or disease, or if a competitor obtains

approval of the same drug as defined by the FDA.

In addition, if an orphan designated product receives marketing approval for

an indication broader than what is designated, it may not be entitled to orphan exclusivity.

exclusivity provisions under the FDCA can delay the submission or approval of certain marketing applications.

The FDCA provides

a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an

NDA for a new chemical entity.

A drug is a new chemical entity if FDA has not previously approved any other new drug containing

the same active moiety, which is the molecule or ion responsible for the action of the drug substance.

During the exclusivity

period, the FDA may not approve or even accept for review an abbreviated new drug application (“ANDA”), or an NDA

submitted under Section 505(b)(2) (a “505(b)(2) NDA”), submitted by another company for another drug based on the

same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for

another indication, where the applicant does not own or have a legal right of reference to all the data required for approval.

However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement

to one of the patents listed with the FDA by the innovator NDA holder.

FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical

investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to

be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug.

This three-year

exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations

and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active ingredient for the original

indication or condition of use.

Five-year and three-year exclusivity will not delay the submission or approval of a full NDA.

However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical

studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

exclusivity is another type of marketing exclusivity available in the United States.

Pediatric exclusivity provides for an additional

six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children

in response to a written request from the FDA.

The issuance of a written request does not require the sponsor to undertake the

described clinical trials.

In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing

exclusivity, except in certain circumstances.

outside the United States of potential drug compounds we develop will also be subject to foreign regulatory requirements governing

human clinical trials and marketing for drugs.

The requirements vary widely from country to country, but typically the registration

and approval process takes several years and requires significant resources.

In most cases, if the FDA has not approved a potential

drug compound for sale in the United States, the potential drug compound may be exported for sale outside of the United States,

only if it has been approved in any one of the following:

the European Union, Canada, Australia, New Zealand, Japan, Israel, Switzerland

and South Africa.

There are specific FDA regulations that govern this process.

resubmitted application also is subject to review before the FDA accepts it for filing.

The FDA may refer an application for a new

drug to an advisory committee within the FDA.

An advisory committee is a panel of independent experts, including clinicians and

other scientific experts, that reviews, evaluates and provides a recommendation as to whether and under what conditions the application

should be approved.

The FDA is not bound by the recommendations of such an advisory committee, but it considers advisory committee

recommendations carefully when making decisions.

Before approving an NDA, the FDA will also

inspect the facility where the product is manufactured.

The FDA will not approve an application unless it determines that the manufacturing

processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product

within required specifications.

Before approving an NDA, the FDA may also inspect one or more clinical trial sites to assure compliance

with GCP requirements.

After the FDA evaluates an NDA, it will issue

an approval letter or a Complete Response Letter.

A Complete Response Letter indicates that the review cycle of the application

is complete, and the application will not be approved in its present form.

A Complete Response Letter usually describes the specific

deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial

or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing.

If a Complete

Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw

the application.

Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria

for approval.

An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications.

The Pediatric Research Equity Act (“PREA”),

requires IND sponsors to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage

form, new dosing regimen or new route of administration.

Under PREA, original NDAs and supplements must contain a pediatric assessment

unless the sponsor has received a deferral or waiver.

The required assessment must evaluate the safety and effectiveness of the

product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric

subpopulation for which the product is safe and effective.

The sponsor or the FDA may request a deferral of pediatric clinical

trials for some or all of the pediatric subpopulations.

A deferral may be granted for several reasons, including a finding that

the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness

data needs to be collected before the pediatric clinical trials begin.

The FDA must send a non-compliance letter to any sponsor

that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric

If a drug receives FDA approval, the approval

may be limited to specific diseases and dosages, which could restrict the commercial value of the product.

In addition, the FDA

may require testing and surveillance programs to monitor the safety of approved products which have been commercialized and may

require a sponsor to conduct post-marketing clinical trials, which are designed to further assess a drug’s safety and effectiveness

after NDA approval.

The FDA may also place other conditions on approval, including a requirement for a risk evaluation and mitigation

strategy (“REMS”) to assure the safe use of the drug.

If the FDA concludes a REMS is needed, the sponsor of the NDA

must submit a proposed REMS.

The FDA will not approve the NDA without an approved REMS, if required.

A REMS could include medication

guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries

and other risk minimization tools.

Any of these limitations on approval or marketing could restrict the commercial promotion, distribution,

prescribing or dispensing of products.

Marketing approval may be withdrawn for non-compliance with REMS or other regulatory requirements,

or if problems occur following initial marketing.

Post-approval requirements

Once an approval is granted, the FDA may withdraw

the approval if compliance with regulatory standards is not maintained or if problems occur after the drug reaches the market.

Later discovery of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of

the drug from the market.

After approval, some types of changes to the approved drug, such as adding new indications, certain manufacturing

changes and additional labeling claims, are subject to further FDA review and approval.

Manufacturers and other entities involved

in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state

agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations

and other laws and regulations.

Any drug product manufactured or distributed

by us pursuant to FDA approval will be subject to continuing regulation by the FDA, including, among other things, record-keeping

requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug

sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with

FDA promotion and advertising requirements.

FDA strictly regulates labeling, advertising, promotion and other types of information

regarding approved drugs that are placed on the market, and imposes requirements and restrictions on drug manufacturers, such as

those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that

are not described in the product’s approved labeling (known as “off-label use”), industry-sponsored scientific

and educational activities, and promotional activities involving the internet.

Discovery of previously unknown problems or the

failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product for a certain

indication or withdrawal of the product from the market as well as possible civil or criminal sanctions.

Failure to comply with

the applicable governmental requirements at any time during the product development process, approval process or after approval,

may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity.

sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing clinical

trials, enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,

fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution,

disgorgement of profits, or civil or criminal penalties.

Expedited development and review programs

The FDA has a fast track designation program

that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria.

Specifically,

new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition

and demonstrate the potential to address unmet medical needs for the disease or condition.

With regard to a fast track product,

the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor

provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines

that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

Any product submitted to the FDA for approval,

including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development

and review, such as priority review and accelerated approval.

A product is eligible for priority review if

it is intended to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared

to currently marketed products.

The FDA will attempt to direct additional resources to the evaluation of an application for a new

drug designated for priority review in an effort to facilitate the review.

The FDA endeavors to review applications with priority

review designations within six months of the filing date, as compared to ten months for review of NDAs under its current PDUFA

review goals.

In addition, a product may be eligible for

accelerated approval.

Drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated

approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical

benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely

to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,

or prevalence of the condition and the availability or lack of alternative treatments.

As a condition of approval, the FDA may

require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials.

Drugs receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required

post-marketing trials or if such trials fail to verify the predicted clinical benefit.

In addition, the FDA currently requires

as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial

launch of the product.

The Food and Drug Administration Safety and

Innovation Act (“FDASIA”) established a category of drugs referred to as “breakthrough therapies” that

may be eligible to receive breakthrough therapy designation.

A sponsor may seek FDA designation of a compound as a “breakthrough

therapy” if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening

disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over

existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical

The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance.

The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be

granted to the same drug if relevant criteria are met.

If a product is designated as breakthrough therapy, the FDA will work to

expedite the development and review of such drug.

Fast track designation, priority review and

breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.

However, even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets

the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

Orphan drug designation

Under the Orphan Drug Act, the FDA may grant

orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer

than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no

reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease

or condition will be recovered from sales of the product.

Orphan designation must be requested before an NDA is submitted.

the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are publicly disclosed by

Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product that has orphan designation subsequently

receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan

product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication

for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity

or inability to manufacture the product in sufficient quantities.

The designation of such drug also entitles a party to financial

incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.

competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain

approval for the same product but for a different indication for which the orphan product has exclusivity.

Orphan exclusivity also

could block the approval of one of our compounds for seven years if our compound is determined to be contained within the competitor’s

product for the same indication or disease, or if a competitor obtains approval of the same drug as defined by the FDA.

if an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled

to orphan exclusivity.

Marketing exclusivity

Market exclusivity provisions under the FDCA

can delay the submission or approval of certain marketing applications.

The FDCA provides a five-year period of non-patent marketing

exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity.

new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule

or ion responsible for the action of the drug substance.

During the exclusivity period, the FDA may not approve or even accept

for review an abbreviated new drug application (“ANDA”), or an NDA submitted under Section 505(b)(2) (a “505(b)(2)

NDA”), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended

for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal

right of reference to all the data required for approval.

However, an application may be submitted after four years if it contains

a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

The FDCA alternatively provides three years

of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability

studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application,

for example new indications, dosages or strengths of an existing drug.

This three-year exclusivity covers only the modification

for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving

ANDAs or 505(b)(2) NDAs for drugs containing the active ingredient for the original indication or condition of use.

Five-year and

three-year exclusivity will not delay the submission or approval of a full NDA.

However, an applicant submitting a full NDA would

be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical

trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of marketing

exclusivity available in the United States.

Pediatric exclusivity provides for an additional six months of marketing exclusivity

attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from

The issuance of a written request does not require the sponsor to undertake the described clinical trials.

orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.

Foreign Sales

Sales outside the United States of potential

drug compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing

The requirements vary widely from country to country, but typically the registration and approval process takes several

years and requires significant resources.

In most cases, if the FDA has not approved a potential drug compound for sale in the

United States, the potential drug compound may be exported for sale outside of the United States, only if it has been approved

in any one of the following:

the European Union, Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa.

are specific FDA regulations that govern this process.

coverage and reimbursement

uncertainty exists as to the coverage and reimbursement status of any compound for which we may seek regulatory approval.

in the United States will depend in part on the availability of sufficient coverage and adequate reimbursement from third-party

payors, which include government health programs such as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as

well as managed care organizations and private health insurers.

Prices at which we or our customers seek reimbursement for our

therapeutic compounds can be subject to challenge, reduction or denial by payors.

process for determining whether a payor will provide coverage for a product is typically separate from the process for setting

the reimbursement rate that the payor will pay for the product.

A payor’s decision to provide coverage for a product does

not imply that an adequate reimbursement rate will be available.

Additionally, in the United States there is no uniform policy

among payors for coverage or reimbursement.

Third-party payors often rely upon Medicare coverage policy and payment limitations

in setting their own coverage and reimbursement policies, but also have their own methods and approval processes.

Therefore, coverage

and reimbursement for products can differ significantly from payor to payor.

If coverage and adequate reimbursement are not available,

or are available only at limited levels, successful commercialization of, and obtaining a satisfactory financial return on, any

product we develop may not be possible.

payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and

services, in addition to their safety and efficacy.

In order to obtain coverage and reimbursement for any product that might be

approved for marketing, we may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness

of any products, which would be in addition to the costs expended to obtain regulatory approvals.

Third-party payors may not consider

our compounds to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required

to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient

to realize an appropriate return on our investment in drug development.

and Abuse Laws

and state health care laws and regulations restrict business practices in the biopharmaceutical industry.

In the biopharmaceutical

industry, there are a number of federal and state health care regulatory requirements that apply to entities, including, but not

limited to, the federal and state fraud and abuse laws.

These laws include, but are not limited to, anti-kickback and self-referral

law, civil false claims act law, criminal false statement law, civil monetary penalty laws, exclusion law, and other civil, criminal,

and administrative laws.

Significant uncertainty exists as to

the coverage and reimbursement status of any compound for which we may seek regulatory approval.

Sales in the United States will

depend in part on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government

health programs such as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations

and private health insurers.

Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject

to challenge, reduction or denial by payors.

The process for determining whether

a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the

payor will pay for the product.

A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement

rate will be available.

Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement.

Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement

policies, but also have their own methods and approval processes.

Therefore, coverage and reimbursement for products can differ

significantly from payor to payor.

If coverage and adequate reimbursement are not available, or are available only at limited levels,

successful commercialization of, and obtaining a satisfactory financial return on, any product we develop may not be possible.

Third-party payors are increasingly

challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition

to their safety and efficacy.

In order to obtain coverage and reimbursement for any product that might be approved for marketing,

we may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products,

which would be in addition to the costs expended to obtain regulatory approvals.

Third-party payors may not consider our compounds

to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure

favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize

an appropriate return on our investment in drug development.

Fraud and Abuse Laws

Federal and state health care laws and

regulations restrict business practices in the biopharmaceutical industry.

In the biopharmaceutical industry, there are a number

of federal and state health care regulatory requirements that apply to entities, including, but not limited to, the federal and

state fraud and abuse laws.

These laws include, but are not limited to, anti-kickback and self-referral law, civil false claims

act law, criminal false statement law, civil monetary penalty laws, exclusion law, and other civil, criminal, and administrative

Health care laws, regulations, and guidance continuously evolve and are thereby subject to constant change.

Federal Anti-Kickback Statute, 42 U.S.C.

§ 1320a-7b(b), among other things, prohibits the knowing and willful offer, payment,

solicitation or receipt of any form of remuneration, whether directly or indirectly and overtly or covertly in cash or in kind,

in return for, or to induce the referral of an individual for the:

furnishing or arranging for the furnishing of items or services reimbursable in whole or in part under Medicare, Medicaid

or other federal healthcare programs;

purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or

service reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs.

are a number of narrow safe harbors to the Federal Anti-Kickback Statute.

Such safe harbors permit certain payments and business

practices that, although they would otherwise potentially implicate the Federal Anti-Kickback Statute, are not treated as an offense

under the same if all of the requirements of the specific applicable safe harbor are met.

Actual knowledge of the statute or specific

intent to violate it is not required in order for a person or entity to have committed a violation.

Federal Anti-Kickback Statute applies to certain arrangements with healthcare providers, product end users and other parties,

including marketing arrangements and discounts and other financial incentives offered in connection with the sales of our products.

Regulatory authorities may determine that certain marketing, pricing, or other activities violate the Federal Anti-Kickback Statute

or other applicable laws.

Noncompliance with the Federal Anti-Kickback Statute can result in civil, administrative and/or criminal

penalties, restrictions on the ability to operate in certain jurisdictions, and exclusion from participation in Medicare, Medicaid

or other federal healthcare programs.

The Federal Anti-Kickback Statute, 42

§ 1320a-7b(b), among other things, prohibits the knowing and willful offer, payment, solicitation or receipt of any

form of remuneration, whether directly or indirectly and overtly or covertly in cash or in kind, in return for, or to induce the

referral of an individual for the:

or arranging for the furnishing of items or services reimbursable in whole or in part under

Medicare, Medicaid or other federal healthcare programs;

lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering

of any item or service reimbursable in whole or in part under Medicare, Medicaid or other

federal healthcare programs.

There are a number of narrow safe harbors

to the Federal Anti-Kickback Statute.

Such safe harbors permit certain payments and business practices that, although they would

otherwise potentially implicate the Federal Anti-Kickback Statute, are not treated as an offense under the same if all of the requirements

of the specific applicable safe harbor are met.

Actual knowledge of the statute or specific intent to violate it is not required

in order for a person or entity to have committed a violation.

The Federal Anti-Kickback Statute applies

to certain arrangements with healthcare providers, product end users and other parties, including marketing arrangements and discounts

and other financial incentives offered in connection with the sales of our products.

Regulatory authorities may determine that

certain marketing, pricing, or other activities violate the Federal Anti-Kickback Statute or other applicable laws.

Noncompliance

with the Federal Anti-Kickback Statute can result in civil, administrative and/or criminal penalties, restrictions on the ability

to operate in certain jurisdictions, and exclusion from participation in Medicare, Medicaid or other federal healthcare programs.

In addition, non-compliance can result in the need to curtail and/or restructure operations.

Any penalties, damages, fines, exclusions, curtailment or restructuring of operations could adversely affect the ability to operate

a business, financial condition, and results of operations.

A violation of the Federal Anti-Kickback Statute can serve as a false

or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute.

Ethics in Patient Referrals Act, commonly known as the “Stark Law,” 42 U.S.C.

§ 1395nn, prohibits a physician

from making referrals for certain “designated health services” payable by Medicare to an entity in which the physician

or an immediate family member of such physician has an ownership or investment interest or with which the physician has entered

into a compensation arrangement, unless a statutory exception applies.

Any penalties, damages, fines, exclusions,

curtailment or restructuring of operations could adversely affect the ability to operate a business, financial condition, and results

of operations.

A violation of the Federal Anti-Kickback Statute can serve as a false or fraudulent claim for purposes of the civil

False Claims Act and the civil monetary penalties statute.

The Ethics in Patient Referrals Act,

commonly known as the “Stark Law,” 42 U.S.C.

§ 1395nn, prohibits a physician from making referrals for certain

“designated health services” payable by Medicare to an entity in which the physician or an immediate family member

of such physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement,

unless a statutory exception applies.

There are a number of exceptions to the Stark Law.

exceptions permit certain payments and arrangements that, although they would otherwise potentially implicate the Stark Law, are

not treated as a violation under the same if the requirements of the specific exceptions are met.

Violation of the Stark Law could

result in denial of payment, disgorgement of reimbursements received under a noncompliance arrangement, civil penalties, damages

and exclusion from Medicare or other governmental programs.

These requirements are highly technical and there can be no guarantee

that regulatory authorities will not determine or assert that arrangements are in violation of the Stark Law and do not otherwise

meet applicable Stark Law exceptions.

federal false statements statute, 42 U.S.C.

§ 1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting

a material fact or making any materially false statement in connection with the delivery of health care benefits, items, or services.

Such exceptions permit certain payments

and arrangements that, although they would otherwise potentially implicate the Stark Law, are not treated as a violation under

the same if the requirements of the specific exceptions are met.

Violation of the Stark Law could result in denial of payment,

disgorgement of reimbursements received under a noncompliance arrangement, civil penalties, damages and exclusion from Medicare

or other governmental programs.

These requirements are highly technical and there can be no guarantee that regulatory authorities

will not determine or assert that arrangements are in violation of the Stark Law and do not otherwise meet applicable Stark Law

The federal false statements statute,

§ 1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting a material fact or making any

materially false statement in connection with the delivery of health care benefits, items, or services.

Similarly, 18 U.S.C.

§ 1035 prohibits a person or entity, in any matter involving a health care benefit program, from knowingly

or willfully falsifying, concealing, or covering up by any trick, scheme, or device a material fact;

making any materially false,

fictitious, or fraudulent statements or representations;

or making or using any materially false writing or document knowing the

same to contain any materially false, fictitious, or fraudulent statement or entry.

In addition to criminal penalties, violation

of these statutes may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid

and other federal health care programs.

§ 669 prohibits knowingly and willfully embezzling, stealing, or otherwise without authority converting to the use

of any person or entity other than the rightful owner, or intentionally misapplying any of the moneys, funds, securities, premiums,

credits, property, or other assets of a health care benefit program.

In addition to criminal penalties, violation of this statute

may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal

health care programs.

criminal health care fraud statute, 18 U.S.C.

§ 1347, establishes criminal liability for whoever knowingly and willfully

executes, or attempts to execute, a scheme or artifice to defraud any health care benefit program, or to obtain, by means of false

or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control

of, any health care benefit program, in connection with the delivery of or payment for health care benefits, items, or services.

In addition to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion

from participation in Medicare, Medicaid and other federal health care programs.

A person or entity need not have actual knowledge

of this law or specific intent to commit a violation of this law.

§ 1518 establishes criminal liability for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent,

obstruct, mislead, or delay the communication of information or records relating to a violation of a Federal health care offense

to a criminal investigator.

In addition to criminal penalties, violation of this statute may result in collateral administrative

sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.

§ 286 establishes criminal liability for whoever enters into any agreement, combination, or conspiracy to defraud

the United States, or any department or agency thereof, by obtaining or aiding to obtain the payment or allowance of any false,

fictitious or fraudulent claim.

1035 prohibits a person or entity, in any matter involving a health care benefit program, from knowingly or willfully falsifying,

concealing, or covering up by any trick, scheme, or device a material fact;

making any materially false, fictitious, or fraudulent

statements or representations;

or making or using any materially false writing or document knowing the same to contain any materially

false, fictitious, or fraudulent statement or entry.

In addition to criminal penalties, violation of these statutes may result

in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care

§ 669 prohibits knowingly

and willfully embezzling, stealing, or otherwise without authority converting to the use of any person or entity other than the

rightful owner, or intentionally misapplying any of the moneys, funds, securities, premiums, credits, property, or other assets

of a health care benefit program.

In addition to criminal penalties, violation of this statute may result in collateral administrative

sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.

§ 287 establishes criminal liability for whoever knowingly makes or presents a false, fictitious or fraudulent claim

to the United States Government, including any department or agency thereof.

The criminal health care fraud statute,

§ 1347, establishes criminal liability for whoever knowingly and willfully executes, or attempts to execute, a scheme

or artifice to defraud any health care benefit program, or to obtain, by means of false or fraudulent pretenses, representations,

or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, in connection

with the delivery of or payment for health care benefits, items, or services.

In addition to criminal penalties, violation of this

1 unchanged sentence

federal health care programs.

Federal False Claims Act, 31 U.S.C.

§ 3729, et seq., provides, in part, that the federal government—or a private party

on behalf of the government—may bring a lawsuit against any person whom it believes has knowingly presented, or caused to

be presented, a false or fraudulent claim for payment, or who has made a false statement or used a false record to get a claim

paid or to avoid, decrease or conceal an obligation to pay money to the federal government or who has knowingly retained an overpayment.

Knowledge under the Federal False Claims Act means actual knowledge, deliberate indifference, or reckless disregard.

amendments in 1986 to the Federal False Claims Act have made it easier for private parties to bring whistleblower lawsuits against

civil monetary penalties law, 42 U.S.C.

§ 1320a-7a, provides, in part, that the federal government may seek civil monetary

penalties against any person who presents or causes to be presented claims to a Federal health care program that the person knows

or should know is for an item or services that was not provided as claimed or is false or fraudulent, or the person has made a

false statement or used a false record to get a claim paid.

The federal government may also seek civil monetary penalties for

a wide variety of other conduct, including offering remuneration to influence a Medicare or Medicaid beneficiary’s selection

of providers and violations of the Federal Anti-Kickback Statute.

of the Federal False Claims Act and/or the Civil Monetary Penalties Law can result in penalties ranging from $11,665 to $23,331

for each false claim violation of the Federal False Claims Act and varying amounts based on the type of violation of the Civil

Monetary Penalties Law, plus up to three times the amount of damages that the federal government sustained.

In addition, the federal

government may also seek exclusion from participation in all federal health care programs.

Section 1320a-7 provides that individuals and entities can be mandatorily or permissively excluded from participation in

federal health care programs.

The grounds for mandatory exclusion include, but are not limited to, conviction for a criminal offense

related to the delivery of an item or service reimbursed under a federal or state health care program, and a conviction related

to health care fraud.

The grounds for permissive exclusion include, but are not limited to, criminal offenses relating to fraud

inside and outside of health care, convictions related to obstruction of an investigation or audit, and/or failure to disclose

certain required information.

Exclusion from federal health care programs—whether mandatory or permissive—may mean

that we would not be entitled to participation in federal and/or state health care programs for services rendered.

Fraud and Abuse Provisions

states have also adopted some form of anti-kickback and anti-referral laws and false claims acts and civil monetary penalties

and other fraud and abuse provisions that apply regardless of payer, in addition to items and services reimbursed under Medicaid

and other state programs.

A determination of liability under such laws could result in fines, penalties, and exclusion, as well

as restrictions on the ability to operate in these jurisdictions.

liability can be present as a result of the illegal activities of employees, representatives, contractors, collaborators, agents,

subsidiaries, or affiliates, even if they were not explicitly authorized.

There can be no assurance that all employees, representatives,

contractors, collaborators, agents, subsidiaries or affiliates will comply with the foregoing laws at all times.

the aforementioned and other laws could result in whistleblower complaints, investigations, sanctions, settlements, prosecution,

government oversight and reporting, other enforcement actions, disgorgement of profits, significant fines, damages, other civil

and criminal penalties or injunctions or other administrative remedies, suspension and/or debarment from contracting with certain

governments or other persons, the loss of privileges, reputational harm, contract damages, adverse media coverage and other collateral

consequences.

In addition, corporate directors, officers, employees, and other representatives who engage in violations of these

and other laws may face imprisonment, fines, and penalties.

If any subpoenas or investigations are launched, or governmental or

other sanctions are imposed, or if a company does not prevail in any possible civil or criminal litigation, business, financial

condition, and results of operations could be materially harmed.

In addition, responding to any action will likely result in a

materially significant diversion of management’s attention and resources and significant defense costs and other professional

Enforcement actions and sanctions could further harm business, financial condition, and results of operations.

consequences contained in this paragraph and section could adversely affect the ability to operate the business, financial condition,

and the results of operations.

Insurance Portability and Accountability Act

Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical

Health Act (“HITECH”), and implementing regulations thereunder (collectively, “HIPAA”) requires certain

healthcare providers, health plans and healthcare clearinghouses who conduct specified electronic healthcare transactions (“covered

entities”), as well as their independent contractors and agents who conduct certain activities involving protected health

information on their behalf (“business associates”) to comply with enumerated requirements relating to the privacy,

security and transmission of protected health information.

Failure to comply with HIPAA can result in corrective action, as well

as civil fines and penalties and government oversight.

Among other changes, HITECH made HIPAA security standards directly applicable

to business associates, increased the tiered civil and criminal fines and penalties that may be imposed against covered entities,

business associates and possibly other persons, and gave state attorneys general new authority to file actions to enforce HIPAA.

Further, the breach notification rule implemented under HITECH requires covered entities to notify affected individuals, the U.S.

Department of Health and Human Services Office of Civil Rights (“OCR”), the agency that enforces HIPAA, and for breaches

affecting more than 500 individuals, the media, of any breaches of unsecured protected health information.

HIPAA does not create

a private right of action for individuals, though individuals may submit complaints related to HIPAA to OCR.

Protection and Affordable Care Act

the United States, there have been, and continue to be multiple legislative and regulatory changes and proposed changes regarding

the healthcare system that could impact our business.

A person or entity need not have actual knowledge of this law or specific intent to commit a violation

§ 1518 establishes criminal

liability for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent, obstruct, mislead, or delay the communication

of information or records relating to a violation of a Federal health care offense to a criminal investigator.

In addition to criminal

penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation

in Medicare, Medicaid and other federal health care programs.

§ 286 establishes criminal

liability for whoever enters into any agreement, combination, or conspiracy to defraud the United States, or any department or

agency thereof, by obtaining or aiding to obtain the payment or allowance of any false, fictitious or fraudulent claim.

to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation

in Medicare, Medicaid and other federal health care programs.

§ 287 establishes criminal

liability for whoever knowingly makes or presents a false, fictitious or fraudulent claim to the United States Government, including

any department or agency thereof.

In addition to criminal penalties, violation of this statute may result in collateral administrative

sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.

The Federal False Claims Act, 31 U.S.C.

§ 3729, et seq., provides, in part, that the federal government—or a private party on behalf of the government—may

bring a lawsuit against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent claim

for payment, or who has made a false statement or used a false record to get a claim paid or to avoid, decrease or conceal an obligation

to pay money to the federal government or who has knowingly retained an overpayment.

Knowledge under the Federal False Claims Act

means actual knowledge, deliberate indifference, or reckless disregard.

In addition, amendments in 1986 to the Federal False Claims

Act have made it easier for private parties to bring whistleblower lawsuits against companies.

The civil monetary penalties law, 42

§ 1320a-7a, provides, in part, that the federal government may seek civil monetary penalties against any person who

presents or causes to be presented claims to a Federal health care program that the person knows or should know is for an item

or services that was not provided as claimed or is false or fraudulent, or the person has made a false statement or used a false

record to get a claim paid.

The federal government may also seek civil monetary penalties for a wide variety of other conduct,

including offering remuneration to influence a Medicare or Medicaid beneficiary’s selection of providers and violations of

the Federal Anti-Kickback Statute.

Violations of the Federal False Claims

Act and/or the Civil Monetary Penalties Law can result in penalties ranging from $11,665 to $23,331 for each false claim violation

of the Federal False Claims Act and varying amounts based on the type of violation of the Civil Monetary Penalties Law, plus up

to three times the amount of damages that the federal government sustained.

In addition, the federal government may also seek exclusion

from participation in all federal health care programs.

Section 1320a-7 provides that

individuals and entities can be mandatorily or permissively excluded from participation in federal health care programs.

for mandatory exclusion include, but are not limited to, conviction for a criminal offense related to the delivery of an item or

service reimbursed under a federal or state health care program, and a conviction related to health care fraud.

The grounds for

permissive exclusion include, but are not limited to, criminal offenses relating to fraud inside and outside of health care, convictions

related to obstruction of an investigation or audit, and/or failure to disclose certain required information.

Exclusion from federal

health care programs—whether mandatory or permissive—may mean that we would not be entitled to participation in federal

and/or state health care programs for services rendered.

State Fraud and Abuse Provisions

Many states have also adopted some form

of anti-kickback and anti-referral laws and false claims acts and civil monetary penalties and other fraud and abuse provisions

that apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs.

A determination

of liability under such laws could result in fines, penalties, and exclusion, as well as restrictions on the ability to operate

in these jurisdictions.

Corporate liability can be present as

a result of the illegal activities of employees, representatives, contractors, collaborators, agents, subsidiaries, or affiliates,

even if they were not explicitly authorized.

There can be no assurance that all employees, representatives, contractors, collaborators,

agents, subsidiaries or affiliates will comply with the foregoing laws at all times.

Violation of the aforementioned and other

laws could result in whistleblower complaints, investigations, sanctions, settlements, prosecution, government oversight and reporting,

other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions

or other administrative remedies, suspension and/or debarment from contracting with certain governments or other persons, the loss

of privileges, reputational harm, contract damages, adverse media coverage and other collateral consequences.

In addition, corporate

directors, officers, employees, and other representatives who engage in violations of these and other laws may face imprisonment,

fines, and penalties.

If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if a

company does not prevail in any possible civil or criminal litigation, business, financial condition, and results of operations

could be materially harmed.

In addition, responding to any action will likely result in a materially significant diversion of management’s

attention and resources and significant defense costs and other professional fees.

Enforcement actions and sanctions could further

harm business, financial condition, and results of operations.

Any of the consequences contained in this paragraph and section

could adversely affect the ability to operate the business, financial condition, and the results of operations.

Health Insurance Portability and

Accountability Act

The Health Insurance Portability and

Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”),

and implementing regulations thereunder (collectively, “HIPAA”) requires certain healthcare providers, health plans

and healthcare clearinghouses who conduct specified electronic healthcare transactions (“covered entities”), as well

as their independent contractors and agents who conduct certain activities involving protected health information on their behalf

(“business associates”) to comply with enumerated requirements relating to the privacy, security and transmission of

protected health information.

Failure to comply with HIPAA can result in corrective action, as well as civil fines and penalties

and government oversight.

Among other changes, HITECH made HIPAA security standards directly applicable to business associates,

increased the tiered civil and criminal fines and penalties that may be imposed against covered entities, business associates and

possibly other persons, and gave state attorneys general new authority to file actions to enforce HIPAA.

Further, the breach notification

rule implemented under HITECH requires covered entities to notify affected individuals, the U.S.

Department of Health and Human

Services Office of Civil Rights (“OCR”), the agency that enforces HIPAA, and for breaches affecting more than 500 individuals,

the media, of any breaches of unsecured protected health information.

HIPAA does not create a private right of action for individuals,

though individuals may submit complaints related to HIPAA to OCR.

Patient Protection and Affordable

In the United States, there have been,

and continue to be multiple legislative and regulatory changes and proposed changes regarding the healthcare system that could

impact our business.

Policymakers and third party reimbursement programs (i.e.

payors) have articulated

the goals of controlling healthcare costs, improving quality and/or expanding access in connection with these healthcare reform

As a leading example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and

Education Reconciliation Act (collectively, the “ACA”), was passed, ushering in significant changes to the way healthcare

is financed in the United States.

With respect to impacts specific to the U.S.

pharmaceutical industry, among other things, the

payors) have articulated the goals of controlling

healthcare costs, improving quality and/or expanding access in connection with these healthcare reform efforts.

As a leading example,

in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively,

the “ACA”), was passed, ushering in significant changes to the way healthcare is financed in the United States.

respect to impacts specific to the U.S.

pharmaceutical industry, among other things, the ACA:

the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program and extended the rebate program to

include Medicaid managed care organizations as well as Medicaid fee-for-service programs;

eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals,

correspondingly increasing manufacturers’ Medicaid rebate liability;

a new methodology by which average manufacturing price is calculated for drugs that are inhaled, infused, instilled, implanted

or injected and not generally dispensed through retail community pharmacies;

• established

an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic

the availability of lower drug pricing under the 340B drug pricing program to additional types of covered entities;

a new partial prescription drug benefit for Medicare recipients under the Medicare Part D coverage gap discount program, in which

manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries

during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part

the Public Health Service Act to create an abbreviated approval pathway for biological products that are demonstrated to be biosimilar

to or interchangeable with an FDA-approved biological product;

a requirement to annually report product samples that manufacturers and distributors provide to physicians;

• established

new requirements, known as “Sunshine Act” requirements for manufacturers of products reimbursed by Medicare, Medicaid

or the Children’s Health Insurance Program (“CHIP”) to collect and annually report detailed data to the Centers

for Medicare and Medicaid Services (“CMS”) regarding payments or other transfers of value to physicians and teaching

hospitals (“covered recipients”), as well as any ownership or investment interest held by physicians and their immediate

family members.

The reporting data must be accompanied by an attestation as to the accuracy of the data and failure to timely

and accurately submit required information may result in civil monetary penalties;

• established

a Center for Medicare & Medicaid Innovation at CMS, to test innovative payment and service delivery models to lower Medicare

and Medicaid spending, potentially including prescription drugs;

a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness

research, along with funding for such research;

healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, and enhanced penalties

for noncompliance, which are applicable beyond the U.S.

expanded eligibility criteria for Medicaid programs by, among other

things, allowing states to offer Medicaid coverage to additional individuals, correspondingly increasing manufacturers’

Medicaid rebate liability;

created a new methodology by which average manufacturing price is calculated

for drugs that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies;

established an annual, nondeductible fee on any entity that manufactures

or imports certain specified branded prescription drugs and biologic products;

expanded the availability of lower drug pricing under the 340B drug

pricing program to additional types of covered entities;

created a new partial prescription drug benefit for Medicare recipients

under the Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off

negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the

manufacturer’s outpatient drugs to be covered under Medicare Part D;

amended the Public Health Service Act to create an abbreviated approval

pathway for biological products that are demonstrated to be biosimilar to or interchangeable with an FDA-approved biological product;

added a requirement to annually report product samples that manufacturers

and distributors provide to physicians;

established new requirements, known as ―Sunshine Act requirements

for manufacturers of products reimbursed by Medicare, Medicaid or the Children’s Health Insurance Program (―CHIP )

to collect and annually report detailed data to the Centers for Medicare and Medicaid Services (―CMS ) regarding payments

or other transfers of value to physicians and teaching hospitals (―covered recipients ), as well as any ownership or investment

interest held by physicians and their immediate family members.

The reporting data must be accompanied by an attestation as to

the accuracy of the data and failure to timely and accurately submit required information may result in civil monetary penalties;

established a Center for Medicare & Medicaid Innovation at CMS,

to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription

created a new Patient-Centered Outcomes Research Institute to oversee,

identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;

expanded healthcare fraud and abuse laws, including the civil False

Claims Act and the federal Anti- Kickback Statute, and enhanced penalties for noncompliance, which are applicable beyond the U.S.

pharmaceutical industry (e.g.

to other types of healthcare entities) but

also are of specific relevance to the U.S.

pharmaceutical industry.

Bipartisan Budget Act of 2018 amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans,

commonly referred to as the “donut hole.” Further, the Substance-Use Disorder Prevention that Promotes Opioid Recovery

and Treatment for Patients and Communities Act (“SUPPORT Act”) amended the Sunshine Act to expand the definition of

covered recipient for whom applicable manufacturers must collect ad report data to include physician assistants, nurse practitioners,

clinical nurse specialists, certified nurse anesthetists and certified nurse mid-wives for data reported on or after January 1,

have been multiple judicial challenges to certain aspects of the ACA, as well as Congressional efforts to repeal or replace the

ACA, and efforts by the Trump administration to delay or circumvent the implementation of certain ACA requirements.

the Tax Cuts and Jobs Act of 2017 repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by

the ACA on certain individuals who fail to maintain minimum essential health care insurance, commonly known as the “individual

mandate.” On December 14, 2018, a U.S.

District Court in the Northern District of Texas ruled that the individual mandate

is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act,

the remaining provisions of the ACA are invalid as well.

to other types of healthcare entities) but also are of specific relevance to the U.S.

pharmaceutical

The Bipartisan Budget Act of 2018 amended

the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut

hole.” Further, the Substance-Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities

Act (“SUPPORT Act”) amended the Sunshine Act to expand the definition of covered recipient for whom applicable manufacturers

must collect ad report data to include physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists

and certified nurse mid-wives for data reported on or after January 1, 2022.

There have been multiple judicial challenges

to certain aspects of the ACA, as well as Congressional efforts to repeal or replace the ACA, and efforts by the Trump administration

to delay or circumvent the implementation of certain ACA requirements.

For example, the Tax Cuts and Jobs Act of 2017 repealed,

effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain

minimum essential health care insurance, commonly known as the “individual mandate.” On December 14, 2018, a U.S.

Court in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and

therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well.

On December 18, 2019, the U.S.

Court of Appeals for the 5th Circuit affirmed

the District Court’s decision that the individual mandate was unconstitutional but remanded the case back to the District

Court to determine whether the remaining provisions of the ACA are invalid as well.

Supreme Court has agreed to review

the case and oral arguments heard oral arguments in November 2020.

Therefore, ongoing force and effect of certain or all of the

provisions of the ACA remain in a state of uncertainty at this current time.

and Development Expenses

Historically,

a significant portion of our operating expenses has related to research and development.

See our Consolidated Financial Statements

contained elsewhere in this Annual Report for costs and expenses related to research and development, and other financial information

for fiscal years 2020 and 2019.

are advised by scientists and physicians with experience relevant to our Company and our product candidates.

Court of Appeals for the 5th Circuit affirmed the District Court’s decision that the individual

mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of

the ACA are invalid as well.

Supreme Court has agreed to review the case and oral arguments heard oral arguments in November

Therefore, ongoing force and effect of certain or all of the provisions of the ACA remain in a state of uncertainty at this

current time.

Research and Development Expenses

Historically, a significant portion

of our operating expenses has related to research and development.

See our Consolidated Financial Statements contained elsewhere

in this Annual Report for costs and expenses related to research and development, and other financial information for fiscal years

2021 and 2020.

Scientific Advisors

We are advised

by scientists and physicians with experience relevant to our Company and our product candidates.

Our scientific advisors

include clinicians and scientists who are affiliated with a number of highly regarded medical institutions.

currently have twenty full-time employees, and we retain several independent contractors on a regular or as-needed basis.

that we have good relations with our employees.

internet website address is www.anavex.com.

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on

Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available

free of charge through our website.

We include our website address in this report only as an inactive textual reference and do

not intend it to be an active link to our website.

We currently have twenty-five full-time

employees, and we retain several independent contractors on a regular or as-needed basis.

We believe that we have good relations

with our employees.

Available Information

website address is www.anavex.com .

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed

or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available free of charge through our website.

our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website.

The contents of our website are not incorporated into this report.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business